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Abstract 
 
Presynaptic nicotinic acetylcholine receptors (nAChRs) and adenosine A2A 
receptors (A2ARs) are key modulators of striatal neurotransmitter release. The 
A2ARs were shown to control the rate of desensitization of different nAChRs in 
the peripheral nervous system and have also been reported to interact, in the 
central nervous system, with other striatal receptors, such as adenosine A1, 
metabotropic glutamate type 5 and CB1 cannabinoid receptors, suggesting the 
possibility for a functional interaction between nAChRs and A2ARs in the 
striatum, with possible relevant implications in dopaminergic disorders like 
Parkinson´s disease (PD). The striatum is the main relay nucleus of the basal 
ganglia, a brain network essential in sensorimotor, cognitive and motivational 
functions. The glutamatergic corticostriatal projections are the leading excitatory 
inputs to the striatum and are controlled by a coordinated interaction among 
several neuromodulators, where the dopaminergic inputs from the substantia 
nigra play a prominent role. The main modulators of striatal functions include 
adenosine, acting at the metabotropic A2ARs, and acetylcholine, which acts at 
ionotropic nAChRs. These two neuromodulation systems have particular 
interest since they are targeted by some of the most widely consumed 
psychoactive drugs worldwide, namely nicotine (a nAChR agonist) and caffeine 
(a nonselective adenosine receptor antagonist); and albeit these two drugs are 
often consumed simultaneously little is known about their combined effects. 
Moreover, epidemiological studies showed that nicotine and caffeine use is 
related with a lower incidence of PD. Notwithstanding, the relation between 
nAChRs and A2ARs is poorly understood, and thus it is important to investigate 
the possible interaction between these types of receptors in striatal neurons. 
The main goal of this study was to investigate the possible functional 
interaction between nAChRs and A2ARs in terms of neurotransmission in the 
striatum. To achieve this goal it was first detailed the synaptic and subsynaptic 
distribution of different nAChR subunits, such as α7, α6, α4 and β2 in stratial 
nerve terminals (synaptosomes), and it was observed that all these subunits, 
which make part of the main nAChRs subtypes, were present in nerve 
terminals. The subsynaptic levels and distribution of α7, α6, α4 and β2 were 
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investigated in the presynaptic active zone, postsynaptic density and in extra-
synaptic fractions (outside the active zone), since the nAChRs might have 
different roles in neurotransmission depending on their localization in the 
different subsynaptic components. The possible presynaptic functional 
interaction between different nAChR subtypes and A2ARs in rat dopaminergic 
nerve terminals was investigated by measuring the in vitro dopamine release 
from striatal nerve terminals and in vivo by assessing the rat locomotor 
sensitization in response to nicotine, in the presence or absence of an A2AR 
antagonist.   
In the rodent striatum we found that the α7 subunit, which predominantly 
makes part of the homomeric α7 nAChR subtype sensitive to α-bungarotoxin, 
was mainly present in the presynaptic active zone. The α4 and β2 subunits 
displayed a similar distribution, being primarily present in presynaptic and in 
extrasynaptic zones, which was expected since these two subunits together 
form heteropentameric nAChRs. By contrast to the former, the α6 subunit was 
mainly present in the postsynaptic fraction, albeit being also present in pre- and 
extra-synaptic fractions. These results underline the possible relevance of 
striatal nAChRs in controlling neurotransmission. 
The in vitro dopamine release studies showed that nicotine elicited the 
release of [3H]dopamine in a concentration-dependent manner from rat striatal 
nerve terminals. Notably, it was observed that the selective A2AR agonist 
CGS21680, significantly inhibited, while ZM241385, an A2AR antagonist, 
significantly potentiated the nicotine-stimulated [3H]dopamine release. The A2BR 
antagonist MRS1754 did not potentiate the release. Adenosine receptor ligands 
CGS21680 and caffeine also stimulated the release of [3H]dopamine per se.  
Antagonists of α6-containing (α6*) and of β2-containing nAChRs, but not of the 
α7 nAChR subtype, significantly inhibited release of [3H]dopamine. Under the 
blockade of the α6* nAChRs the remaining nicotine-stimulated [3H]dopamine 
release was no longer subject to modulation by A2AR ligands, indicating that the 
α6β2* nAChRs function is coupled to A2ARs.  
The in vivo relevance of the interplay between α6β2* nAChRs and A2ARs 
was also assessed. In locomotor sensitization experiments it was observed that 
nicotine significantly augmented the locomotor activity of rats from the day 7 of 
nicotine injection, but it no longer persisted after 8 days of abstinence. 
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ZM241385-injected rats developed locomotor sensitization to nicotine already 
on day 2 of injection, which was not blunted by the 8 day drug-free period, 
reinforcing the contention for a functional interaction between the α6β2* 
nAChRs and the A2ARs. Altogether, this work details the striatal subsynaptic 
density of some of the main nAChR subunits and provides the first evidence for 
a functional interaction between nicotinic and adenosine receptors in striatal 
dopaminergic terminals, with likely therapeutic consequences for Parkinson’s 
disease, nicotine addiction and other dopaminergic disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
xx 
 
Resumo 
 
Os receptores colinérgicos nicotínicos (nAChRs) e os receptores A2A de 
adenosina (A2ARs) pré-sinápticos são moduladores importantes da libertação 
de neurotransmissores no estriado. Foi demonstrado que os A2ARs controlam a 
taxa de desensitização de diferentes nAChRs no sistema nervoso periférico e 
foi também relatado que, no sistema nervoso central, interagem com outros 
receptores estriatais, tais como receptores A1 de adenosina, metabotrópicos de 
glutamato do tipo 5 e canabinóides CB1, sugerindo a possibilidade de uma 
interação funcional entre nAChRs e A2ARs no estriado, com possiveis 
implicações relevantes em distúrbios dopaminérgicos como a doença de 
Parkinson (PD). O estriado é o principal núcleo retransmissor dos gânglios da 
base, uma rede cerebral essencial em funções sensorimotoras, cognitivas e 
motivacionais. As projecções glutamatérgicas cortico-estriatais são a principal 
fonte de entrada excitatória no estriado e são controladas por uma interação 
coordenada entre diversos neuromoduladores, onde as entradas 
dopaminérgicas provenientes da substância nigra desempenham um papel 
fundamental. Os principais moduladores de funções estriatais incluem a  
adenosina, atuando nos A2ARs metabotrópicos, e a acetilcolina, que atua nos 
nAChRs ionotrópicos. Estes dois sistemas neuromoduladores têm particular 
importância já que são alvo de algumas das drogas psicoactivas mais 
consumidas mundialmente, nomeadamente a nicotina (um agonista dos 
nAChRs) e a cafeína (um antagonista não-selectivo dos receptores de 
adenosina); e embora estas duas drogas sejam frequentemente consumidas 
em simultâneo, pouco se sabe acerca dos seus efeitos combinados. Para além 
disso, estudos epidemiológicos mostraram que o uso de nicotina e cafeína está 
relacionado com uma menor incidência da PD. Contudo, a relação entre  
nAChRs e A2ARs é deficientemente conhecida, e portanto é importante 
investigar a possivel interação entre estes tipos de receptores em neurónios 
estriatais. 
O principal objectivo deste estudo foi investigar a possivel interação 
funcional entre nAChRs e A2ARs em termos de neurotransmissão no estriado. 
Para atingir este objectivo foi primeiro detalhada a distribuição sináptica e sub-
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sináptica de diferentes subunidades de nAChRs, tais como α7, α6, α4 e β2 em 
terminais nervosos estriatais (sinaptossomas), e foi observado que todas estas 
subunidades, que formam parte dos principais subtipos de nAChRs, estavam 
presentes em terminais nervosos. Foram investigados os niveis sub-sinápticos 
e a distribuição das α7, α6, α4 e β2, na zona activa pré-sináptica, densidade 
pós-sináptica e em fracções extra-sinápticas (fora da zona activa), dado que os 
nAChRs podem ter diferentes papéis na neurotransmissão dependendo da sua 
localização nos diferentes componentes sub-sinápticos. A possível interação 
funcional pré-sináptica entre diferentes subtipos de nAChRs e A2ARs em 
terminais dopaminérgicos de rato foi investigada in vitro através da medição da 
libertação de dopamina de terminais nervosos estriatais e in vivo pela avaliação 
da sensitização locomotora de ratos em resposta a nicotina, na presença ou 
ausência de um antagonista dos A2ARs. 
No estriado de roedores observou-se que a subunidade α7, que faz 
predominantemente parte do subtipo α7 de nAChRs homomérico sensível à α-
bungarotoxina, estava principalmente presente na zona activa pré-sináptica. As 
subunidades α4 e β2 exibiram uma distribuição semelhante entre si, estando 
primariamente presentes em zonas pré-sinápticas e extra-sinápticas, o que é 
esperado dado que estas duas subunidades juntas formam nAChRs 
heteropentaméricos. Em contraste com as anteriores, a subunidade α6 estava 
principalmente presente na fracção pós-sináptica,  embora estando também 
presente em fracções pré- e extra-sinápticas. Estes resultados sublinham a 
possível relevância de nAChRs estriatais em controlar a neurotransmissão. 
Os estudos in vitro de libertação de dopamina mostraram que a nicotina 
provocou a libertação de [3H]dopamina de um modo dependente da 
concentração, de terminais nervosos estriatais de rato. De modo relevante, foi 
observado que o agonista selectivo dos A2ARs CGS21680, inibiu 
significativamente, enquanto que ZM241385, um antagonista dos A2ARs, 
potenciou significativamente a libertação de [3H]dopamina estimulada por 
nicotina. O antagonista dos A2BRs, MRS1754, não potenciou a libertação. Os 
ligandos dos receptores de adenosina CGS21680 e cafeína também 
estimularam a libertação de [3H]dopamina per se. Antagonistas de subtipos de 
nAChRs que contém a subunidade α6 (α6*) e de subtipos que contém a 
subunidade β2, mas não do subtipo α7 de nAChRs, inibiram significativamente 
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a libertação de [3H]dopamina. Sob bloqueio dos α6* nAChRs a restante 
libertação de [3H]dopamina estimulada por nicotina já não foi sujeita a 
modulação por ligandos dos A2ARs, indicando que a função dos α6β2* nAChRs 
está acoplada aos A2ARs. 
A relevância in vivo da cooperação entre os α6β2* nAChRs e os A2ARs foi 
também avaliada. Em experiências de sensitização locomotora foi observado 
que a nicotina aumentou significativamente a actividade locomotora de ratos a 
partir do dia 7 de injecção de nicotina, mas que o aumento já não persistiu 
depois de 8 dias de abstinência. Ratos injectados com ZM241385 
desenvolveram sensitização locomotora à nicotina logo no dia 2 de injecção, 
que não foi diminuída pelo período de 8 dias livre de fármacos, reforçando os 
indícios quanto a uma interação funcional entre os α6β2* nAChRs e os A2ARs. 
No seu conjunto, este trabalho detalha a densidade estriatal sub-sináptica 
de algumas das principais subunidades de nAChRs e providencia a primeira 
evidência para uma interação funcional entre receptores nicotínicos e de 
adenosina em terminais dopaminérgicos estriatais, com prováveis 
consequências terapêuticas para a doença de Parkinson, dependência 
nicotínica e outros distúrbios dopaminérgicos. 
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1.1 THE STRIATUM 
 
The striatum is a subcortical structure of the brain that constitutes one of 
the main components of the basal ganglia, a neural network essential in 
sensorimotor, cognitive and motivational brain functions (Bolam et al., 2000; 
Schiffmann et al., 2007). The striatum acts as a major relay nucleus between 
the neocortex and the deeper nuclei of the basal ganglia. Based on connectivity 
and function the striatum is divided into a dorsal part, the neostriatum, which 
consists of the caudate nucleus and the putamen (dorsal striatum), and a 
ventral portion that is mainly composed by the nucleus accumbens (NAc) and 
also by the olfactory tubercle (ventral striatum). Other main constituents of the 
basal ganglia are the globus pallidus (GP, also called paleostriatum), which in 
primates is divided into external (GPe) and internal (GPi) segments, the 
entopeduncular nucleus (EP, in rodents, equivalent to primates GPi), 
subthalamic nucleus (STN) and the substantia nigra (SN) (see Fig. 1.1). The SN 
is divided into two main parts, the dorsal pars compacta (SNc) where the 
dopaminergic nigrostriatal neurons are located and the more ventral pars 
reticulata (SNr), containing GABAergic neurons (Bolam et al., 2000; Havekes et 
al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 - Location of the neostriatum (caudate nucleus-putamen) and other 
main structures of the basal ganglia in the human brain (source: 
http://www.g2conline.org/#Brain?aid=2092). 
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The striatum receives extensive thalamo-cortical inputs which, after being 
integrated at the striatal level, are processed by the basal ganglia output nuclei 
and subsequently sent back to thalamic and cortical areas (see Fig. 1.3) 
(Graybiel 1991). This processing occurs through an orchestrated interaction 
among several neuromodulators at the pre- and post-synaptic levels (Girault 
2012), where the dopaminergic inputs from the SN play a prominent role 
(Gerfen and Surmeier, 2011).  Accordingly, the dopaminergic system is crucial 
in different functions processed through striatal circuits, such as locomotor 
activity, habit formation or associative and mnemonic functions (Wickens et al., 
2007; Dagher and Robbins, 2009; Lovinger 2010; Cools 2011). Also, the 
manipulation of different neuromodulators, including acetylcholine (ACh) and 
adenosine, can affect the striatal dopaminergic system and hence is a potential 
strategy to manage striatal-related brain diseases associated with dopaminergic 
dysfunction such as Parkinson’s disease (PD) and addiction (Schiffmann et al., 
2007; Quik et al., 2011). 
The majority of striatal 
neurons are efferent inhibitory 
GABAergic medium sized 
spiny neurons (MSNs) 
(Fig.1.2), which constitute 
about 95% of the neuronal 
population of the striatum 
(Rymar et al., 2004). MSNs 
have dendrites densely 
covered with dendritic spines, 
giving them their name, and 
are divided into two major 
subpopulations, the enkephalinergic and the dynorphinergic neurons, based on 
their neurochemical content and different projection regions. These distinct 
neuronal types originate two different pathways (see Fig. 1.3) that link the 
striatum with the output nuclei of the basal ganglia: i) the direct pathway, formed 
by dynorphinergic neurons that express the neuropeptide substance P and ii) 
the indirect pathway constituted by enkephalinergic neurons that express 
enkephalin (Ferré et al., 1997; Gerfen 2004). The MSNs of the direct pathway 
 
Figure 1.2 – (A) Photomicrograph of Golgi-
impregnated medium spiny neurons from monkey 
putamen. (B) high-magnification of dendritic 
branches (C) detail of a dendritic branch with 
dendritic spines (source: 
http://www.emory.edu/NEUROSCIENCE/Smith/hey
neindex.htm).  
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are directly connected to output nuclei of the basal ganglia, such as the internal 
segment of the globus pallidus (GPi, or entopeduncular nucleus in rodents), and 
their stimulation results in motor activation, while the MSNs of the indirect 
pathway project almost exclusively to the external section of the globus pallidus 
(GPe or globus pallidus in rodents) and when stimulated originate motor 
inhibition (Fig. 1.3) (see Smith et al., 1998 for review). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The striatum (caudate-putamen) is the main processing unit of the basal 
ganglia, and receives direct input from glutamatergic efferents from virtually all 
regions of the neocortex and also from limbic and thalamic areas (see Fig. 1.3). 
The striatum functioning implies an interface role between the neocortex and 
the deeper nuclei of the basal ganglia. That is, cortical inputs are processed via 
Figure 1.3 - Schematic model of the major connections of basal ganglia circuits. 
Blue arrows indicate GABAergic connections (inhibitory), red arrows indicate 
glutamatergic connections (excitatory), green arrows indicate dopaminergic 
connections and the orange arrow represents cholinergic connections. Cortical 
activation of the direct pathway (striatum–GPi/SNr) promotes movement while 
stimulation of the indirect pathway (striatum–GPe–STN–GPi/SNr–thalamus) has the 
opposite effects. SNc, substantia nigra pars compacta; SNr, substantia nigra pars 
reticulata; GPi, internal segment of globus pallidus or entopeduncular nucleus in 
rodents; GPe, external segment of globus pallidus; PPN, pedunculopontine nucleus; 
STN, subthalamic nucleus.  
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changes in synaptic plasticity at cortico-MSNs glutamatergic synapses. The 
neuromodulators adenosine, dopamine and acetylcholine are essential 
elements in the control of striatal synaptic plasticity (for review see Lerner and 
Kreitzer, 2011) and, therefore, anything that alters the delicate balance among 
these neuromodulators will have profound effects on motor functions, behaviour 
and personality. 
The striatum receives substantial dopaminergic efferents from the 
mesencephalon, the majority originating in the substantia nigra pars compacta, 
and in the ventral tegmental area (VTA) to a lesser extent (Gerfen 2004). Both 
the glutamatergic and the dopaminergic sets of inputs target the dendritic 
spines of MSNs, but converge at different locations. Cortical projections form 
mainly asymmetrical synapses with the head of dendritic spines, whereas 
dopaminergic terminals primarily form symmetric synaptic contacts with the 
necks of dendritic spines (see Ferré et al., 2007) (Fig. 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Representation of a striatal medium spiny neuron (MSN) and 
dendritic spine detail. This type of neuron receives glutamatergic afferent inputs from 
cortical and thalamic areas, and dopaminergic afferents from the mesencephalon. The 
enlarged scheme shows a dendritic spine of the MSN and glutamatergic and 
dopaminergic terminals, which make synaptic contact with the head and neck of the 
dendritic spine, respectively (adapted from Ferré et al., 2007). 
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glutamatergic input
Medium spiny neuron
(striatum)
Mesencephalic
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Dendritic spine
Glutamatergic terminal
Dopaminergic terminal
Introduction 
7 
 
This morphological organization results in different functions: the 
glutamatergic input acts as a trigger of striatal circuits, while the dopaminergic 
input has an essential modulatory role, given that it is incapable of triggering 
electrical responses in MSNs without glutamatergic inputs (Bolam et al., 2000; 
Gerfen 2004). Besides the MSNs, the neuronal population of the striatum is 
composed by cholinergic interneurons (~2%) and at least three types of 
GABAergic interneurons (~5%) (Kawaguchi et al., 1995; Ferré et al., 2007). 
These GABAergic interneurons receive input from the cortex and are 
strategically positioned to integrate and modulate the arriving cortical 
information. The large cholinergic interneurons are responsible almost 
exclusively for the neostriatal cholinergic innervation (Havekes et al., 2011).  
      
1.2 NEUROMODULATION IN THE STRIATUM 
1.2.1 Dopaminergic neuromodulation  
 
As described in the previous section, the structural organization of the 
striatal neurons allows the modulation of glutamatergic excitatory inputs from 
the cortex, limbic system and thalamus by mesencephalic dopaminergic inputs 
(mainly from the SN). Dopaminergic neurons display two general and well-
defined firing modes in vivo; single-spike firing in regular or irregular patterns 
(∼1–10 Hz) and burst firing of 3–5 spikes at a frequency of ∼15–100 Hz (Grace 
and Bunney, 1984a,b; Hyland et al., 2002) and the switch in firing mode of 
these neurons, from low to higher firing frequencies, is thought to be 
responsible for the encoding of information (Threlfell and Cragg, 2011). 
Although dopaminergic neurons constitute a relatively small population, a single 
dopaminergic neuron projecting to the striatum forms a very dense arbor 
(Matsuda et al., 2009; Moss and Bolam, 2010). An individual dopaminergic 
neuron is believed to make several hundred thousand synapses, at least an 
order of magnitude higher than most other neurons of the central nervous 
system (CNS) (Matsuda et al., 2009). Thus, dopaminergic neurons are well-
positioned to serve as modulators of striatal functions.  
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Dopamine (DA) acts via the activation of 5 subtypes of metabotropic G 
protein-coupled receptors, classified as D1, D2, D3, D4, and D5. The receptors D1 
(D1Rs) and D5 (D5Rs) are classified as D1R-like, and activate the enzyme 
adenylate cyclase; the D2Rs, D3Rs and D4Rs are termed D2R - like subtypes,  
and those receptors inhibit adenylate cyclase (Missale et al., 1998). The two 
populations of MSNs, enkephalinergic and dynorphinergic, have marked 
differences in the types of dopamine (and also adenosine) receptors that they 
express, which underlies their function in the modulation of striatal information 
flow. The dynorphinergic neurons of the direct pathway express principally D1Rs 
and A1 subtype adenosine receptors (A1Rs), while the enkephalinergic neurons 
that form the indirect pathway display mainly dopamine D2Rs (D2LR isoform) 
and adenosine A2A receptors (A2ARs) (Ferré et al., 1997). Therefore, dopamine 
will induce motor activation in two different ways: by activating D1Rs of the 
direct pathway and on the other hand by depressing the indirect pathway 
through the action at inhibitory D2Rs in enkephalinergic neurons (Gerfen 2004). 
Besides acting at synaptic contacts in dendritic spines of MSNs, dopamine can 
spill over from the synapses (process called volume transmission) and activate 
extrasynaptic dopamine receptors (Ferré et al., 2007). Since approximately 60-
70 % of dopaminergic axon terminals do not form synaptic contacts (Descarries 
et al., 1996; Vizi et al., 2010) dopamine can also diffuse away from non-synaptic 
dopaminergic terminals and activate the extrasynaptic dopamine receptors 
(mainly localized in the vicinity of glutamatergic synapses on MSNs) (Yung et 
al., 1995; Venton et al., 2003). Presynaptic D2/4Rs can be localized in 
glutamatergic terminals (Tarazi et al., 1998; Bamford et al., 2004) and in 
dopaminergic terminals of synaptic contacts made with enkephalinergic MSNs, 
behaving as autoreceptors (Sesack et al., 1994; Usiello et al., 2000). 
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1.2.2 Cholinergic neurotransmission 
  
It has been recognized for some time that the striatum is enriched in 
cholinergic innervation (Satoh 1983) suggesting that acetylcholine (ACh) has an 
important function in this brain region (Ferré et al., 2007; Havekes et al., 2011). 
The striatal concentrations of ACh and of cholinergic enzymes, 
acetylcholinesterase and choline acetyltransferase, are among the highest in 
the brain (Hoover et al., 1978); and the striatum also contains high densities of 
muscarinic (mAChRs) and nicotinic acetylcholine receptors (nAChRs) (Aubert et 
al., 1996; Grady et al., 2007). Apart from a minor projection arising from the 
pedunculopontine nucleus (PPN) (Woolf and Butcher, 1986; Nakano et al., 
1990) the neostriatal cholinergic innervation is performed by the intrinsic large 
aspiny cholinergic interneurons. These cells possess smooth dendrites and are 
distributed in a characteristic pattern throughout the neostriatum and probably 
correspond to the tonically active neurons recorded in vivo (Apicella 2007). Only 
a relatively small number (~10%) of striatal cholinergic synaptic specializations 
have been identified, targeting MSNs, which indicates that ACh in the striatum 
acts mainly via nonsynaptic (paracrine or nonjunctional) and diffuse (volume) 
transmission (Descarries et al., 1997). The basal levels of ACh in the striatum 
(DeBoer et al., 1993) appear to be high enough to continuously activate the 
cholinergic receptors (Kurosaki et al., 1987; Quirion et al., 1989), establishing a 
baseline and tonic level of cholinergic neurotransmission. 
The ACh-mediated modulation of dopamine transmission in the striatum 
notably involves presynaptic mechanisms, mediated by nAChRs localized 
mainly in dopaminergic but also in glutamatergic nerve terminals. The 
cholinergic and dopaminergic neurons have dense overlapping axonal 
arborizations and a high density of dopaminergic and cholinergic terminals 
exists in the striatum, often separated only by about 1 μm (Descarries et al., 
1997). Therefore, striatal ACh (or an exogenous agonist such as nicotine) 
acting at nAChRs is able to effectively modulate dopamine release by direct and 
indirect (glutamate mediated) mechanisms (Ferré et al., 2007). 
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Figure 1.5 – Representation of a 
nicotinic acetylcholine receptor showing 
the side (a) and synaptic (b) views 
(taken from Halliwell 2007). 
1.3 CLASSIFICATION AND STRUCTURE OF NICOTINIC 
ACETYLCHOLINE RECEPTORS  
  
Nicotinic acetylcholine receptors (nAChRs) are widely distributed in the 
central and peripheral nervous systems. The neuronal nAChRs belong to a 
large superfamily of ligand-gated ion channels. This superfamily of homologous 
ionotropic receptors also includes: muscle-type acetylcholine receptors, gama-
aminobutyric acid receptors (GABAAR and GABACR) glycine receptors and the 
serotonin (5-HT) receptors, 5-HT3R (Le Novere et al., 2002; Gotti et al., 2007).  
The neurotransmitter ACh, firstly identified in 1914, functions as the 
endogenous agonist of nAChRs, while the alkaloid nicotine (from where the 
name of the receptors derive), is one of the best know exogenous agonists. 
Functionally, the nAChRs in the brain mediate classical excitatory cholinergic 
neurotransmission at selected loci but also, and perhaps more globally, play 
important roles in the modulation of neurotransmission by other chemical 
messengers (Wu and Lukas, 2011). Therefore, nAChRs are involved in a 
number of higher brain functional processes, including cognition, learning and 
memory, arousal, reward, neuronal development and in several pathological 
conditions, such as Parkinson´s disease, Alzheimer’s disease, depression, 
epilepsy, schizophrenia and addiction (Levin and Simon, 1998; Paterson and 
Nordberg, 2000; Hogg et al., 2003; Graef et al., 2011).  
The nAChRs consist of five 
subunits assembled in the plasma 
membrane to form a barrel like 
channel (Fig. 1.5) that is permeable for 
the monovalent Na+ and K+ ions, and 
also for Ca2+. The many possible 
combinations in which the different 
nAChR subunits can potentially co-
assemble lead to a diversity of distinct 
nAChR subtypes. The cation 
permeability of the different subtypes is 
influenced by their subunit composition 
(Fucile 2004). Twelve neuronal nAChR 
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subunit genes have so far been cloned and classified into two subfamilies of 
nine alpha (α2– α10) and three beta subunits (β2– β4). To date, two main 
classes of nAChR subtypes have been identified: the homomeric or heteromeric 
α-bungarotoxin (α-BTX) sensitive receptors, which are made up of the α7, α8, 
α7-α8, α9 and/or α10 subunits, and the heteromeric α-BTX-insensitive receptors 
consisting of the α (α2–α6) and β (β2–β4) subunits (Gotti et al., 2007; 
Albuquerque et al., 2009). It should be noted that some studies report that the 
α7 subunit can also form functional heteromeric receptors with β subunits 
(Palma et al., 1999; Khiroug et al., 2002; Liu et al., 2009, 2012). Heteromeric 
subtypes generally assemble according to a 2α3β stoichiometry, with the 
possibility of existing more than one α subunit type within the pentamer. 
Homomeric α7, α8 and α9 are able to form functional homopentamers 
composed by a single subunit subtype (the α8 subtype only being found in 
aviary tissue). Presently, six α (α2– α7) and three β (β2– β4) subunits have 
been identified in mammalian brain (Paterson and Nordberg, 2000; Gotti et al., 
2006b) (see Fig. 1.6). These receptors share a common basic structure, but 
have specific pharmacological and functional properties that are consequence 
of the very different subunit combinations that make distinctive subtypes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 – Organization and structure of homopentameric and 
heteropentameric subtypes of nAChRs. Localization of the subunit interfaces of the 
ACh-binding site are shown below. The homomeric α7 subtype has five identical 
acetylcholine (ACh) binding sites per receptor molecule (one on each subunit interface) 
while the heteropentameric receptors have two identical binding sites per receptor 
molecule (taken from Gotti et al., 2006b). 
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The assembly of nAChRs is a strongly regulated and well-organized 
process, which requires appropriate subunit–subunit interactions (see Millar and 
Harkness, 2008). In that way, although there is potential for the formation of 
nAChRs with different subunit combinations, the native nAChRs identified are 
assembled into subtypes containing a relatively restricted number of subunit 
combinations, which nonetheless originate a substantial diversity of nAChRs. 
The basic structure of nAChR subunits (Fig. 1.7) consists of a relatively 
hydrophilic extracellular amino terminal domain of ~200 amino acids that 
contains the ACh binding site and faces the synaptic cleft, followed by three 
segments of 19-27 amino acids that form compact hydrophobic transmembrane 
domains (M1–M3), a large intracellular loop, a fourth hydrophobic 
transmembrane domain (M4) and a final small carboxyl-terminal sequence. The 
M1–M4 transmembrane domains are arranged in concentric layers around the 
central aqueous pore: the M2 domain lines the pore membrane, M1 and M3 
shield M2 from the surrounding lipid bilayer and M4 is the most exposed to 
lipids (Unwin 2005; Albuquerque et al., 2009, Gotti et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 – Nicotinic receptor structure showing the hydrophilic extracellular domain 
containing the ACh binding site, the four transmembrane segments  M1-M4, the 
intracellular loop and the small C terminal domain. Highlighted in the box is the 
transmembrane segment M2 which is thought to form the lining of the ion channel 
(taken from Paterson and Nordberg, 2000). 
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Both α and β subunits contribute to the pharmacological properties of the 
receptor binding site(s). The binding site has principal and complementary 
components, and is located at the interface between two identical subunits in 
homomeric α7 receptors, or between an α and a β subunit in the case of 
heteromeric α-BTX-insensitive receptors (see Fig. 1.6). The α5 and β3 subunits 
do not have the primary or the complementary components of the ACh binding 
site, and it is generally believed that they do not directly participate in its 
formation. It is thought that homomeric receptors have five identical ACh-
binding sites for each receptor molecule (one on each subunit interface), 
whereas the heteromeric receptors have two binding sites per receptor 
(Corringer et al., 2000). 
Neuronal nicotinic receptors can be 
localized at the nerve terminal boutons, at 
the presynaptic active zone; at the terminal 
boutons but outside the active zone, or in 
preterminal axon segments, where they 
directly modulate the release of almost all 
neurotransmitters or influence the 
probability of exocytosis of 
neurotransmitters. However, these 
receptors can also be present at 
somatodendritic postsynaptic locations 
(see Fig. 1.8) (Wessler 1992; Wonnacott 
1997; Dani and Bertrand, 2007; 
Albuquerque et al., 2009).  There are also increasing evidences that several 
neuronal-type nAChR subunits are expressed in non-excitable cells such as 
microglia, astrocytes and endothelial cells (Wessler and Kirkpatrick, 2008; 
Albuquerque et al., 2009). Many different nAChR subtypes have been identified 
in various regions of the CNS (see Fig 1.9) and while those subtypes can be 
localized in different parts of the neuronal cells currently the prevalent idea is 
that nAChRs present at presynaptic or preterminal sites are physiologically 
more relevant (Sher et al., 2004; Jensen et al., 2005).  
 
 
Figure 1.8 – Putative locations of 
neuronal nicotinic acetylcholine 
receptors (taken from Wonnacott 
1997). 
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1.4 DISTRIBUTION AND LOCALIZATION OF NICOTINIC RECEPTOR 
SUBUNITS 
 
1.4.1 Alpha 7 (α7) subunit 
 
The α7 subunits form mainly homomeric receptors, designated as the α7 
nAChR subtype, that are found in vertebrate central and autonomic nervous 
systems and have the ability to bind the curaremimetic neurotoxin α-
bungarotoxin (Morley et al., 1979; Clarke et al., 1992; Lukas et al., 1992). This 
nAChR subtype has a high Ca2+ permeability (Dajas-Bailador and Wonnacott, 
2004), undergoes rapid activation and desensitisation (Wu and Lukas, 2011) 
and has a low affinity for agonists (Köfalvi et al., 2000; Albuquerque et al., 2009; 
Toyohara and Hashimoto 2010).  In the CNS, α7 nAChRs are located primarily 
in the hippocampus, thalamus, prefrontal cortex, subcortical basal ganglia, 
ventral midbrain and dorsal raphe nucleus (Gotti et al., 2007; Bencherif and 
Lippiello, 2010). This nAChR subtype has been implicated in processes such as 
Figure 1.9 – Regional distribution of some of the main nicotinic receptor 
subtypes in the rodent central nervous system (taken from Gotti et al., 2006b). 
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control of neurotransmitter release (Albuquerque et al., 2000), development and 
maintenance of neurites and synapses (Freeman 1977; Pugh and Berg, 1994), 
long-term potentiation (Hunter et al., 1994), neuronal viability/death (Renshaw 
1994; Hory-Lee and Frank 1995) and modulation of immunological responses 
(Conejero-Goldberg et al., 2008). 
The α7 nAChRs are predominant in the hippocampus, where they can be 
found postsynaptically on the soma and dendrites of pyramidal neurons and 
GABAergic interneurons (Albuquerque et al., 2009). In the basal ganglia there is 
also a relevant expression of α7 nAChRs, with higher levels detected in the SN, 
and lower in the caudate nucleus and putamen, as demonstrated by radioligand 
binding of [125I]α-bungarotoxin in human brain (Court et al., 2000). At the cellular 
level α7 nAChRs were identified in the cell bodies of dopaminergic and 
GABAergic neurons of the VTA (Klink et al., 2001; Jones et al., 2004), of 
GABAergic neurons of the prefrontal cortex (Lubin et al., 1999) and in 
postsynaptic sites of cortical excitatory synapses (Levy and Aoki, 2002). A 
presynaptic localization of α7 nAChRs can also occur and this receptor subtype 
has been identified in glutamatergic and GABAergic terminals in several brain 
regions such as striatum (Marchi et al., 2002), hippocampus (Fabian-Fine et al., 
2001; Maggi et al., 2003), olfactory bulb (Alkondon et al., 1996), VTA (Jones 
and Wonnacott, 2004), medial habenula (Girod and Role, 2001) and frontal 
cortex (Rousseau et al., 2005).  
There is expression of α7 nAChR subunit mRNA in some midbrain 
dopaminergic neurons (Azam et al., 2002), and it was also suggested the 
presence of α7 nAChRs in dopaminergic terminals (Soliakov et al., 1995); 
however, the inability of these receptors to influence [3H]dopamine release from 
isolated nerve terminals (Grady et al., 1992; Mogg et al., 2002; Salminen et al., 
2004) seems to indicate that this subtype may be restricted to somatodendritic 
regions of dopamine neurons.  
Accumulating evidences also support the existence of heteromeric 
nAChRs formed by α7 and β2 or β3 subunits (Palma et al., 1999; Khiroug et al., 
2002; Liu et al., 2009, 2012).  
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1.4.2 Beta 2 (β2) subunit 
  
The β2 subunit of nAChRs is the most widespread in the brain and can 
form different nAChR subtypes when it assembles with other subunits, namely 
with the α4 subunit (forming the α4β2* receptors, where the asterisk denotes 
the possible presence of other subunits in the receptor complex) or with the α6 
subunit (forming α6β2* receptors). These subtypes are present in numerous 
brain areas, such as the striatum, hippocampus, SN, VTA or NAc (Gotti et al., 
2007, Albuquerque et al., 2009).  
The β2 subunit can also assemble with α3 and α2 subunits, forming 
nAChRs containing, α2, α3 and β2 subunits, designated as α2β2* and α3β2*, 
respectively. The α3β2* subtype was identified in rodent retina, cerebellum and 
habenulo-interpeduncular pathway (Marritt et al., 2005; Turner and Kellar, 2005; 
Grady et al., 2009). This receptor subtype was also identified in monkey 
striatum (Quik et al., 2005), but does not appear to be significantly present in 
rodent striatum as previously thought (Zoli et al., 2002). In situ hybridization 
studies have shown that the α2β2* subtype is highly expressed in several areas 
of primate brain (Han et al., 2003) but its expression in rat is limited to retina 
and interpeduncular nucleus (Moretti et al., 2004; Grady et al., 2009), 
suggesting that there are differences between the subtypes of nAChRs 
expressed in primate and rodent brains. 
 
1.4.3 Alpha 4 (α4) subunit 
  
Nicotinic receptors that contain the α4 subunit (α4* nAChRs) are highly 
abundant in the brain, displaying a wide distribution throughout many regions, 
that include the neocortex, striatum, hippocampus, ventral midbrain, most of the 
thalamic nuclei and the dorsomedial hypothalamic nucleus (Gotti et al., 2007; 
Wu and Lukas, 2011). Immunoassays have shown that the predominant 
naturally expressed form of α4* nAChRs in the vertebrate brain contains α4 and 
β2 subunits, forming the α4β2 nAChR subtype (Whiting et al., 1987; Flores et 
al., 1992). The α4 colocalizes with the β2 subunit in most brain areas and 
knocking down either one abolishes high affinity nicotinic agonist binding 
(Picciotto et al., 2001). The α4β2 receptors are expressed in two different 
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stoichiometries: i) the (α4)2(β2)3 stoichiometry that binds to ACh and nicotine 
with high affinity, and ii) the (α4)3(β2)2 stoichiometry that binds to ACh and 
nicotine with low affinity (Zwart et al., 1998; Khiroug et al., 2004). The α4β2 
nAChRs have been implicated in nicotine self-administration, reward, 
dependence and in brain diseases, such as Alzheimer’s disease and epilepsy 
(Wu and Lukas, 2011). 
In the striatum the α4β2 subtype is present in dopaminergic and 
GABAergic neurons, while a subtype that also contains the α5 subunit (α4α5β2 
nAChR subtype) has distinct properties and is mostly expressed by 
dopaminergic terminals (Zoli et al., 2002), but may also exist in GABAergic 
interneurons (McClure-Begley et al., 2009). The α4 subunit is also included in 
subtypes of more complex nAChRs composition, which contain the α6* subunit 
(α4α6β2β3 nAChR subtype), localized on striatal dopaminergic nerve terminals 
(see Figs. 1.6 and 1.9). Pharmacological profiles compatible with that of α4β2 
nAChRs were also identified on cholinergic terminals in the human neocortex 
and in the rat midbrain (Diaz-Hernandez et al., 2004). In addition to being 
expressed on presynaptic terminals, α4β2 nAChRs have been reported in 
axonal pre-terminal regions of GABAergic neurons in the VTA and hippocampus 
and in thalamocortical neurons (Alkondon et al., 1999; Mansvelder et al., 2002; 
Kawai et al., 2007).The α4β2* nAChRs are also present in somatodendritic sites 
in several brain areas, such as the SN and VTA, where they are located in 
dopaminergic and GABAergic cell bodies and in hippocampal neurons (Klink et 
al., 2001; Albuquerque et al., 2009; Livingstone and Wonnacott, 2009). 
The α4 subunit can also assemble with β4 subunits to form α4β4 nAChRs, 
which have comparably high nicotine affinity (Moaddel et al., 2005; Hamouda et 
al., 2009). The β4 subunit mRNA colocalizes with α4 subunit mRNA in several 
brain regions (Winzer-Serhan and Leslie, 1997; Quik et al., 2000) and the 
presence of α4β4 nAChRs has been suggested in the interpeduncular nucleus 
(Klink et al., 2001), cerebellum and retina (Marritt et al., 2005; Turner and 
Kellar, 2005). 
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1.4.4 Alpha 6 (α6) subunit  
 
Nicotinic receptors that contain the α6 subunit (α6-containing nAChRs, 
α6*) were one of the last to be characterized, with the cloning of the α6 nAChR 
subunit only achieved in the 1990s (Deneris et al., 1991; Sargent, 1993; Quik et 
al., 2011). These receptors appear to be excluded from the peripheral nervous 
system and exhibit a relatively restricted distribution in the mammalian CNS 
(Quik et al, 2006; Calabresi et al., 2008; Yang et al., 2009; Millar et al., 2009). 
Studies with in situ hybridization, in rodent and primate brain, done to identify 
the presence of α6 nAChR subunit mRNA, showed that the strongest α6 mRNA 
signal is in the retina and catecholaminergic nuclei, including the locus 
coeruleus, VTA and SN, with a weaker signal in the superior colliculus, medial 
habenula, interpeduncular nucleus, visual cortex and a few other small nuclei 
(Le Novere et al., 1996; Quik et al., 2000; Han et al., 2000; Champtiaux et al., 
2002). This anatomical distribution suggests that α6* nAChRs may play a role in 
behaviours linked to reward, motor activity and vision. Studies with α6 nAChR-
subunit directed antibodies and the snail toxin α-conotoxin MII (α-CTX MII), 
which binds to α6β2* nAChRs, revealed that the α6* nAChRs are present in the 
mesolimbic and nigrostriatal dopaminergic pathways, and are consistent with 
the existence of α6 mRNA in catecholaminergic nuclei (Whiteaker et al., 2000; 
Quik et al., 2001; Zoli et al., 2002; Gotti et al., 2005). Immunoprecipitation 
experiments found that α6* nAChRs account for 30% of [3H]epibatidine binding 
sites in striatum (Champtiaux et al., 2003), and quantitative immunoprecipitation 
showed that most of α6* nAChRs (87%) disappeared in 6-hydroxydopamine (6-
OHDA) lesioned striatum (Zoli et al., 2002), suggesting a regulatory function of 
presynaptic α6* nAChRs in dopamine release (Salminen et al., 2004; Azam and 
McIntosh, 2005). These results indicate that α6* nAChRs appear to be 
preferentially addressed to dopaminergic nerve terminal compartments since 
the majority of dopaminergic neurons in the SN project to the striatum (Zoli et 
al., 2002; Champtiaux et al., 2003; Yang et al., 2009). Recent findings indicate 
that there are also functional α6* nAChRs located on GABAergic presynaptic 
boutons (Yang et al., 2011) and that α6* nAChRs may also be located on 
somatodendrites of VTA dopaminergic neurons (Drenan et al., 2008), but the 
presence of postsynaptic α6* nAChRs in the striatum has not been clearly 
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reported yet. The α6* nAChRs (α-CTX MII-binding nAChRs) localized at nerve 
terminals appear to be expressed almost exclusively in dopaminergic neurons 
(Quik et al., 2011). 
Immunological approaches using a battery of subunit specific antibodies to 
measure the nAChR subtypes identified three α6* nAChR subtypes: α4α6β2β3, 
α6β2β3 and α6β2 in rodent striatum (Zoli, 2002; Champtiaux et al., 2003; Gotti 
et al., 2005), that have different pharmacological properties. These α6* nAChR 
subtypes are probably the ones that bind [125I]-α-CTX MII with high affinity 
(Grady et al., 2007). Immunological methods have also identified these 
subtypes of receptors in striatal tissue obtained from squirrel monkeys (Quik et 
al., 2005) and humans (Gotti et al., 2006a). 
Studies with parkinsonian animal models, including mice, rats and 
monkeys, suggest that nicotine or nAChR agonist treatment may afford 
therapeutic benefit in PD by interacting with nAChRs, especially the α4α6β2β3 
subtype (O’Neill et al., 2002; Quik et al., 2007; Picciotto et al., 2008; Huang et 
al., 2009). Binding studies in striatal tissue revealed that the α4α6β2β3 is a 
subtype that is preferentially vulnerable, since it is lost with mild to moderate 
nigrostriatal damage in animal models and human patients of PD, whereas the 
α6β2β3 was only decreased with more severe damage (Bordia et al., 2007; 
Gotti et al, 2009). Several studies with rodents and monkeys have also showed 
that nicotine administration reduces abnormal involuntary movements caused 
by the administration of levodopa, also named L-dopa (L-3,4-
dihydroxyphenylalanine) (Quik et al., 2007; Bordia et al., 2008; Huang et al., 
2011) and recent results suggest that the neuroprotective nicotine effects are 
mediated through the α6β2* nAChRs (Quik et al., 2012a). 
Extensive work has been done to investigate the role of a6* subtypes in 
dopaminergic activity in the striatum, the terminal region of the nigrostriatal 
pathway. The nAChRs were shown to be able to modulate dopamine release 
from striatal synaptosomes (Rapier et al., 1988; Grady et al., 1992), a function 
which was thought to be regulated only by α4β2* (non-α6) nAChRs. However, it 
was later revealed that activation of the subtype α6β2β3* also stimulated 
[3H]dopamine release from striatal nerve terminals and that these two nAChR 
subtypes appear to promote dopamine release in similar proportions in rodent 
striatum (Kulak et al., 1997; Kaiser et al., 1998). Interestingly, the α6β2β3* 
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Figure 1.10 – Adenosine intracellular 
synthesis and metabolism (taken from 
Xie et al., 2007). 
nAChR subtype seems to be even more predominant in nonhuman primate 
striatum, with 80% of [3H]dopamine release being mediated by α6β2β3 nAChR 
subtypes and only 20% by the α4β2* nAChR population (McCallum et al., 2005, 
2006). 
Overall, α6* nAChRs appear to play a prominent role in modulating striatal 
dopamine release. Recently it has become apparent that presynaptic nAChRs 
may act through a “filtering” action, modulating the activity of dopaminergic 
neurons during bursting and tonic firing patterns, influencing dopamine release 
probability instead of simply enhancing neurotransmitter release from 
dopaminergic neurons (Zhou et al., 2001; Rice et al., 2004; Zhang and Sulzer, 
2004, Exley and Cragg, 2008). These receptors seem to play a crucial role in 
controlling motor function, and may therefore represent novel therapeutic 
targets for the treatment of movement disorders, such as PD (Quik et al., 2011). 
 
1.5 ADENOSINE METABOLISM 
 
Adenosine is a purine nucleoside 
that is present ubiquitously in the body, 
and is permanently produced both 
intra- and extracellularly in normal 
conditions (Cunha 2005) (Fig. 1.10). 
Intracellularly, it is formed from 
adenosine monophosphate nucleotides 
(AMP) by the activity of an endo-5’-
nucleotidase enzyme or from S-
adenosyl-homocysteine by S-adenosyl-
homocysteine hydrolase. Adenosine 
can be integrated back in S-adenosyl-
homocysteine, metabolized into inosine 
by adenosine deaminase or back into AMP by adenosine kinase. Adenosine of 
intracellular source can be released to the extracellular space by bi-directional 
equilibrative nucleoside transporters (ENTs) (Latini and Pedata, 2001). 
Adenosine can also be formed in the extracellular space through the catabolism 
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of exocytotic-released ATP (Cunha et al., 1996; Dunwiddie et al., 1997). In this 
pathway, ATP is converted into AMP by an ATPase and/or ATP 
diphosphohydrolase enzyme and then the AMP is subsequently converted to 
adenosine by the activity of an ecto-5’-nucleotidase enzyme (see Zimmermann 
1996; Cunha 2001). Extracellular adenosine is removed, by neurons and 
astrocytes,   through the uptake mediated by specific nucleoside transporters, 
i.e. the ENTs and the concentrative nucleoside transporters (CNTs) (Latini and 
Pedata, 2001; Nam et al., 2012). The intracellular concentration of adenosine in 
energetically non-deprived cells is estimated to be between 10-50 nM and the 
basal extracellular concentration is predicted to range between 50-200 nM 
(Latini and Pedata, 2001).  The functions played by adenosine in the CNS are 
diverse and include cell-to-cell signaling, modulation of cellular metabolic status, 
metabolism of nucleotides, nucleosides and amino acids (Cunha 2005).  
 
 
1.6 ADENOSINE RECEPTORS: STRUCTURE, DISTRIBUTION AND 
LOCALIZATION 
 
Adenosine acts through adenosine receptors which are classified into four 
different subtypes: A1, A2A, A2B and A3 (designated as A1R, A2AR, A2BR and A3R). 
All of them are membrane spanning proteins with seven transmembrane 
domains (see Fig. 1.11), belonging to the superfamily of metabotropic G 
protein-coupled receptors. In the CNS, adenosine receptors are widely 
distributed. The A1Rs are the most abundant and widespread, being highly 
expressed in the cortex, hippocampus, cerebellum, spinal cord and thalamus, 
on neurons and also on glial cells (Fastbom et al., 1987; Schindler et al., 2001; 
Cunha 2005). A1Rs are also expressed in the basal ganglia at lower densities 
(Fastbom et al., 1987). The A2ARs (Fig. 1.11) are the second most abundant 
adenosine receptor subtype in the CNS and are predominantly concentrated in 
the basal ganglia, although also being present throughout the brain at 
considerably lower levels, in areas such as the cortex, hippocampus and 
cerebellum (Svenningsson et al., 1999; Fredholm et al., 2003). In the basal 
ganglia, A2ARs are mainly expressed in the caudate-putamen, NAc, olfactory 
tubercle and globus pallidus (Svenningsson et al., 1999; Rosin et al., 2003; 
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Figure 1.11 – Representation of the 
crystallographic structure of the 
human adenosine A2A receptor, bound 
to the antagonist ZM241385 (dark 
blue) (taken from Jaakola and 
Ijzerman, 2010). 
Fredholm et al., 2005). At the cellular level 
A2ARs are not only expressed in neurons 
but also in astrocytes (Nishizaki et al., 
2002) and microglia (Küst et al., 1999). 
The A2BRs and A3Rs are the less abundant 
in the brain. The A2BRs are reported to 
have a widespread distribution in the brain, 
although at low levels (Dixon et al., 1996), 
and have been identified in diverse 
locations such as the median eminence of 
the hypothalamus, eye, blood vessels and 
pituitary gland. A2BRs appear to be mainly 
expressed in astrocytes but are also 
present in neurons (Allaman et al., 2003; 
Fredholm et al., 2005). Due to their low expression and to the lack of selective 
pharmacological tools, the distribution and function of this subtype is still largely 
unknown. The A3Rs are expressed at low density in several brain regions, 
including the striatum, cortex, hippocampus and cerebellum, in neuronal and 
glial cells (Dixon et al., 1996, Cunha 2005).  
In striatum A1Rs and A2ARs are found both pre- and post-synaptically, 
predominantly localized at the contacts between cortico-thalamic glutamatergic 
projections and GABAergic medium spiny neurons, but also in the neck of 
dendritic spines of these MSNs (Hettinger et al., 2001; Ferré et al., 2007). The 
A2ARs are more densely expressed postsynaptically in the MSNs, but are also 
present presynaptically in the active zone of the glutamatergic nerve terminals 
(Rebola et al., 2005). Aside from MSNs, the A2ARs are also expressed in 
cholinergic interneurons (Preston et al., 2000; Tozzi et al., 2011). Notably, 
postsynaptic A2ARs are almost exclusively expressed by the enkephalinergic 
subtype of MSNs that form the indirect pathway in the striatum (Svenningsson 
et al., 1999; Gerfen et al., 2004). Adenosine receptors are also localized at 
dopaminergic synapses, where A1Rs are found presynaptically (Borycz et al., 
2007). Given that A2ARs do not control directly the release of dopamine in the 
striatum the presence of functional A2ARs in the dopaminergic striatal afferents 
has been contentious until recently, but compelling data, including work from 
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our laboratory, provided experimental evidence for the existence of A2ARs in 
dopaminergic terminals of the striatum (see Chowdhury and Fillenz, 1991; 
Gomes et al., 2006, 2009 and Garção et al., 2013). 
 
1.7 NEUROMODULATION BY ADENOSINE RECEPTORS IN THE 
STRIATUM 
 
Adenosine receptors are thought to play an essential role in the regulation 
of neurotransmission in the striatum, which is emphasized by their cellular and 
subcellular distribution in this brain region (Rebola et al., 2005; Morelli et al., 
2009). The modulation of cortico-thalamic excitatory glutamatergic transmission 
is a main focus for adenosine receptors in controlling striatal functions 
(Schiffmann et al., 2007). Activation of A1Rs leads to a decrease in probability 
of neurotransmitter release (Lovinger and Choi, 1995; Flagmeyer et al., 1997), 
and on the contrary, activation of A2A receptors increases the probability of 
neurotransmitter release through cAMP-PKA or PKC dependent mechanisms 
(Fredholm et al., 2005; Leenders and Sheng, 2005), such as occurs in the 
A2ARs localized in striatal glutamatergic terminals, leading to the increase of 
evoked glutamate release (Ciruela et al., 2006). Activation of A2A receptors has 
also been reported to lead to the stimulation of striatal dopamine and 
acetylcholine release (Kurokawa et al., 1994; Okada et al., 1996), although 
these actions are still not fully understood (Schiffmann et al., 2007). 
Presynaptic A2ARs were described to colocalize with metabotropic 
glutamate type 5 (mGluR5) receptors in striatal glutamatergic terminals and it 
was observed that there is a synergistic effect between these receptors on the 
facilitation of glutamate release (Rodrigues et al., 2005). Moreover, presynaptic 
A2ARs participate in an inhibitory interaction with cannabinoid CB1 receptors 
(CB1Rs) in the striatum, where they generate opposite effects on glutamate 
release and on signal transduction pathways (Martíre et al., 2011). The co-
localization and functional interaction between A2ARs and CB1Rs in 
corticostriatal glutamatergic terminals was also confirmed by work developed in 
our research group (Ferreira et al., unpublished results). It was also reported 
that presynaptic A2ARs and A1Rs in glutamatergic terminals can form receptor 
heteromers that modulate glutamate release through antagonistic reciprocal 
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interactions (Ciruela et al., 2006; Quiroz et al., 2009). Postsynaptically, the 
enkephalinergic MSNs that express predominantly facilitatory A2ARs also 
express inhibitory D2 dopamine receptors (D2Rs), while the dynorphinergic 
MSNs express predominantly inhibitory A1Rs and facilitatory D1 dopamine 
receptors (D1Rs) (Gerfen 2004). There are evidences supporting a close 
functional interaction between the adenosine and dopamine receptors in the 
MSNs of both the direct and indirect pathways. It was shown that the function of 
the dynorphinergic neurons is modulated by antagonistic interactions between 
A1Rs and D1Rs, whereas the enkephalinergic neurons are modulated by 
antagonistic interactions between A2ARs and D2Rs (Ferré et al., 1997, 2005), 
which were reported to be responsible for most of the locomotor depression and 
activation caused by A2AR agonists and antagonists, respectively (Ferré et al., 
2008). The A2ARs localized in the enkephalinergic MSNs can also form 
heteromeric complexes with the inhibitory receptors, D2Rs and mGlu5R, which 
contribute to modulate postsynaptic plastic changes at the glutamatergic 
synapses (Ferré et al., 2007). In this way, both presynaptic and postsynaptic 
adenosine receptors, in close interaction with other receptors types work to 
insure an efficient regulation of the motor function.  
 
1.8 ROLE OF STRIATAL NICOTINIC AND ADENOSINE RECEPTORS 
IN PATHOPHYSIOLOGY AND NEUROPTOTECTION 
 
The presence of nicotinic and adenosine receptors in neuronal afferents to 
the striatum, as well as the well-known epidemiological data obtained from 
consumers of nicotine and caffeine (a general adenosine receptor antagonist) 
(Ascherio et al., 2001; Schwarzschild et al., 2003; Quik et al., 2012b) position 
the nicotinic and adenosine receptors as potential therapeutic targets in brain 
pathologies, such as PD. 
PD is a neurodegenerative disorder characterized by a progressive loss of 
dopaminergic neurons in the substantia nigra pars compacta and consequent 
loss of function of the nigrostriatal dopaminergic system (Schapira and Jenner, 
2011). The major clinical symptoms of this devastating disease include reduced 
spontaneous movement, rigidity, bradykinesia (slowness of movements), 
akinesia (lack of movement) and resting tremor (Armentero et al., 2011; 
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Halliday et al., 2011). The reduction in striatal DA transmission that occurs in 
the parkinsonian brain is believed to increase the inhibitory output from the 
basal ganglia to the thalamus, leading to impaired motor function (Lester et al., 
2010). To date, only palliative interventions are available to the majority of 
parkinsonian patients. 
Data obtained from epidemiological studies were essential in identifying 
potentially protective agents against PD. Two of the most noteworthy, and 
relevant to our study, are nicotine and caffeine. Nicotine constitutes 
approximately 0.6-3% of the dry weight of a tobacco plant, and is a potent 
natural insecticide (Hurst et al., 2013). About 1 billion people worldwide are 
tobacco smokers and consumption of tobacco products is increasing globally 
(World Health Organization, 2013). The recognition that tobacco use is related 
with a lower incidence of PD led to the consideration of nicotine as a possible 
therapeutic agent (see Quik et al., 2012b)  and studies with animal models 
reinforced the idea that nicotine or other nAChR agonists may be an efficient 
treatment for the motor symptoms of PD. Activation of nAChRs was shown to 
modulate locomotion in non-lesioned animals and to improve motor dysfunction 
symptoms in animals with nigrostriatal damage (Schneider et al., 1998; Meshul 
et al., 2002). Moreover, nicotine treatment was shown to protect the nigrostriatal 
dopaminergic neurons from degeneration after administration of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-OHDA (Costa et al., 2001; 
Parain et al., 2003), two toxins widely used to induce parkinsonian-like 
symptoms. The most relevant nAChRs to PD pathophysiology are probably the 
ones in the nigrostriatal pathway, although receptors in other brain areas could 
also play important roles (Quik et al., 2009). The loss of dopaminergic 
presynaptic terminals in PD is accompanied by a decrease in nAChRs (Quik et 
al., 2004; Bohr et al., 2005); and although the identity of the affected nAChR 
subtypes is not well-defined, a number of studies have indicated a prominent 
involvement of α4β2* and α6β2* receptors (Gotti and Clementi, 2004; Quik and 
McIntosh, 2006). Notably, these nAChR subtypes seem to be differentially 
affected by nigrostriatal damage since studies with parkinsonian rodents and 
monkeys indicate that the α6α4β2* nAChR subtype is more prone to damage 
than the α6(non-α4)β2* or α4β2* nAChR population, and similar observations 
were obtained in the brain of PD patients (Bordia et al., 2007).  
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Caffeine is the most widely consumed psychoactive drug worldwide 
(Fredholm et al., 1999). The consumption of caffeine, a non-specific adenosine 
A1/A2A receptor antagonist, was also associated with a reduced risk of 
developing PD (Ascherio et al., 2001; Schwarzschild et al., 2003). Moreover, it 
was reported that caffeine ameliorates the loss of striatal dopamine induced by 
acute MPTP administration in mice (Chen et al., 2001) and conferred 
neuroprotection in a model of unilaterally intrastriatal 6-OHDA-lesioned rats 
(Joghataie et al., 2004). Other studies with more selective adenosine receptor 
ligands highlighted the major neuroprotectant role for the blockade of A2ARs 
(see Cunha 2005; Schwarzschild et al., 2006). Genetic deletion of A2ARs 
prevented striatal dopamine depletion in mice intraperitoneally injected with 
MPTP (Chen et al., 2001) and A2AR antagonists were shown to be 
neuroprotective in a PD rat model where 6-OHDA was infused inside the 
striatum (Ikeda et al., 2002). The A2AR antagonist ZM241385 was shown to 
protect PC12 cells against the dopaminergic neurotoxins 1-methyl-4-
phenylpyridinium (MPP+) and methamphetamine (Scatena et al., 2011) and to 
inhibit oxidative stress in the striatum of rats with nigrostriatal neurons damaged 
by 6-OHDA (Gołembiowska and Dziubina, 2012). Also, the use of the selective 
A2AR antagonist SCH58261 potentiated rotational behavior produced by 
levodopa in 6-OHDA-lesioned rats (Fenu et al., 1997) and prevented the death 
of nigral dopaminergic neurons caused by sub-chronic MPTP administration in 
mice (Carta et al., 2009). In non-human primates intraperitoneally injected with 
MPTP it was shown that the administration of another selective A2AR 
antagonist, istradefylline (KW-6002), also increased locomotor activity (Kanda 
et al., 1998), and the co-administration of KW-6002 with a threshold dose of 
levodopa enhanced the motor response of animals without increasing 
dyskinesias (Kanda et al., 2000), which are a side-effect caused by levodopa 
treatment. Therefore, the blockade of the A2ARs appears to provide a functional 
protection of striatal dopamine transmission, and also prevent the loss of 
dopaminergic pathway neurons caused by neurotoxins (e.g. MPTP and 6-
OHDA). 
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2. AIM 
 
 
The main objective of this work was to detail the possible functional 
interaction between nAChRs and A2ARs in the striatum. 
 
 
 
To accomplish this goal the following aims were addressed: 
 
 
- Investigate the synaptic and subsynaptic distribution of the α7, α6, α4 and β2 
subunits of nAChRs in the striatum of rodents. 
 
- Characterize in vitro the functional interaction between nAChRs and A2ARs in 
the control of dopamine release in striatal nerve terminals. 
 
- Assess the in vivo impact of the interaction between nAChRs and A2ARs by 
analyzing the locomotor activity of rats.  
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Figure 3.1 – Wistar rat 
3.1 BIOLOGICAL MATERIAL AND PREPARATIONS 
 
All studies were conducted in accordance with the principles and 
procedures outlined as “Replacement, Refinement and Reduction of Animals in 
Research” (3Rs) in the guidelines of EU (86/609/EEC), FELASA, the National 
Centre for the 3Rs (the ARRIVE; Kilkenny et al., 2010), and the Animal Care 
Committee of the Center for Neuroscience and Cell Biology of Coimbra. 
Moreover, we also applied the principles of the ARRIVE guideline for the design 
and the execution of in vitro pharmacological experiments (see below) as well 
as for data management and interpretation, according to McGrath et al., 2010. It 
should be referred that different tissues from the animals employed in our study 
were used in other on-going projects at our research centers. 
 
3.1.1 Animals 
  
The animals used in the experiments 
presented in this thesis were male Wistar rats (10-14 
weeks old) (Fig. 3.1) and male C57BL/6 mice (10-12 
weeks old) (Fig. 3.2) obtained from Charles River 
(Barcelona, Spain). The animals were housed under 
controlled temperature (23±2 ºC), subject to a fixed 
12 h light/dark cycle, with free access to food and 
water. All efforts were made to reduce the number of 
animals used and to minimize their stress and 
discomfort. 
The animals used to perform the in vitro studies 
were deeply anesthetized with halothane (no 
reaction to handling or tail pinch, while still breathing) 
before decapitation with a guillotine. 
 
 
 
 
 
Figure 3.2 – C57BL/6 mouse  
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3.1.2 Synaptosomal preparations 
 
Isolated nerve terminals, termed synaptosomes (Whittaker et al., 1964; 
Whittaker 1993) (Fig. 3.3), represent an excellent standard tool to study 
presynaptic processes free of polysynaptic and glial influences (for review see 
Raiteri and Raiteri, 2000). Synaptosomes are formed when brain tissue is 
homogenized in an isotonic solution of appropriate viscosity and using suitable 
shear force. The nerve terminals, or synaptic boutons, are this way detached 
from their axons and from the postsynaptic terminals and glial cells to which 
they were connected (Dunkley et al., 2008). Their membranes then reseal, 
forming a closed vesicular structure, ranging in size between 0.5-2 µm of 
diameter (Dunkley et al., 1988) that maintains the nerve terminal contents, 
including functional ion channels, carriers and receptors, synaptic vesicles, 
cytoplasm, mitochondria and cytoskeleton together with their functionality (Bai 
and Witzmann, 2007).  
 
 
 
 
 
 
 
 
 
 
Synaptosomal preparations thus retain Ca2+-buffering capacity and 
physiological plasma membrane potential (-60 to -70 mV), which is regulated by 
a Na+/K+-ATPase. The application of depolarizing stimuli (e.g., potassium or 4-
aminopyridine) leads to the entry of Ca2+ into the synaptosomes through 
voltage-operated Ca2+ channels (VOCCs) and triggers exocytosis of docked 
synaptic vesicles, releasing neurotransmitters into the extracellular medium 
Figure 3.3 – High resolution views of intact, sealed synaptosomes (pre), containing 
synaptic vesicles (SV) and mitochondria (pre+M). Adjacent postsynaptic elements 
(post) containing electron dense elements (PSD) are also visible, along with tubular 
and vesicular structures (TV) (taken from Corera et al., 2009).  
pre 
pre 
pre 
SV 
SV 
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(Breukel et al., 1997). Similarly, nAChRs agonists such as nicotine are also able 
to induce neurotransmitter release from synaptosomes by increasing cytosolic 
Ca2+, both directly (e.g. through the α7 nAChR channel) and indirectly by 
recruiting VOCCs activated by the depolarization caused by Na+ influx through 
predominantly non-α7 nAChR subtypes (Dickinson et al., 2008). Synaptosomal 
preparations are viable and retain their function for several hours if maintained 
at low temperatures (0-4 ºC), supplemented with glucose.  
Frequently, a part of the postsynaptic membrane and its attached 
postsynaptic density will remain attached to the presynaptic nerve terminal (see 
Figure 3.3). However, the use of sucrose or Percoll density-gradient 
centrifugation techniques allows the obtention of preparations enriched in 
presynaptic nerve terminals. Synaptosomes are therefore an excellent 
preparation to study expression of neuronal synaptic proteins and investigate 
synaptic functions such as neurotransmitter release (Whittaker 1993). 
 
3.1.2.1 Partially purified synaptosomes (P2 fraction) 
 
The animals were decapitated and their brains quickly removed into ice-
cold sucrose solution (0.32 M, containing 5 mM HEPES, pH 7.4). The caudate-
putamen region of the striata, without the nucleus accumbens (from now simply 
designated as striatum) were quickly dissected out into 2 ml ice-cold sucrose 
solution, homogenized with a Teflon homogenizer, and centrifuged at 5,000 g 
for 5 min. The supernatant was centrifuged at 13,000 g for 10 min to obtain the 
P2 synaptosomal fraction (Ferreira et al., 2009). 
 
3.1.2.2 Synaptosomes purified by a 45% percoll gradient 
  
Rodent striatal nerve terminals were prepared using a combined 
sucrose/Percoll centrifugation protocol as previously described (Rebola et al., 
2005). Briefly, the two striata from one animal were homogenized with a Teflon 
homogenizer in an ice-cold sucrose-HEPES medium containing 0.32 M 
sucrose, 1 mM EDTA, 0.1% BSA and 10 mM HEPES (pH 7.4). The 
homogenate was spun at 3,000 g for 10 min at 4ºC and the supernatant spun 
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again at 14,000 g for 12 min. The pellet (P2 fraction) was resuspended in 1 ml 
of Percoll 45% (v/v) made up in Krebs-HEPES-Ringer (KHR) medium (in mM: 
NaCl 140, EDTA 1, KCl 5, glucose 5 and HEPES 10, pH 7.4) and spun again at 
14,000 g for 2 min. Synaptosomes were then removed from the top layer and 
washed once with KHR medium at 14,000 g for 2 min. The synaptosomal pellet 
obtained was solubilized in 5% SDS supplemented with 100 µM PMSF, 2 mM 
DTT and a protease inhibitor cocktail (containing 1 μg/ml of leupeptin, pepstatin 
A, chymostatin, and antipain). The protein concentration was then determined 
using the bicinchoninic acid (BCA) protein assay reagent.  
 
3.1.2.3 Subsynaptic fractionation of nerve terminals 
  
The presynaptic active zone, postsynaptic and extrasynaptic fractions from 
rodent striatal synaptosomes were separated according to the method 
previously described by Phillips et al., 2001, with some modifications introduced 
by our group (Rebola et al., 2005) (Fig. 3.4). It was observed that this 
subsynaptic fractionation 
method allows an over 90% 
effective separation of the 
presynaptic active zone 
(enriched in SNAP-25 and 
syntaxin), postsynaptic 
density (enriched in 
PSD95) and the non-active 
fraction or extrasynaptic 
zone (synaptophysin). By 
determining the levels of 
these synaptic proteins 
(SNAP 25, syntaxin, 
PSD95 and synaptophysin) 
it is possible to estimate the 
relative purity of the different isolated subsynaptic fractions (Rebola et al., 
2005). These subsynaptic fractions can be useful to assess the subsynaptic 
  
Figure 3.4 – Schematic representation of the 
procedure for subcellular fractionation of nerve 
terminals. Isolated synaptosomes are first 
solubilized with Triton at pH 6.0, separating the 
soluble fraction (Extrasynaptic Fraction) from the 
synaptic junctions (insoluble). This pellet is then 
solubilized with Triton at pH 8.0 which dissociates the 
presynaptic active zone (Presynaptic Fraction) from 
the postsynaptic density (Postsynaptic Fraction) 
(taken from Rodrigues et al., 2005).  
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distribution of receptors by Western blot analysis (see Rebola et al., 2005; 
Rodrigues et al., 2005).  
Briefly, striata from 5-8 rats or 10-12 mice were homogenized at 4°C in 2.5 
ml of isolation solution [0.32 M sucrose, 0.1 mM CaCl2, 1 mM MgCl2, 0.1 mM 
phenylmethylsulfonylfluoride (PMSF)]. The concentration of sucrose was raised 
to 1.25 M by addition of 12 ml of 2 M sucrose and 5 ml of 0.1 mM CaCl2 and the 
suspension divided into 2 ultracentrifuge tubes. The homogenate was overlaid 
with 2.5 ml of 1.0 M sucrose and 0.1 mM CaCl2, and the volume of the tubes 
adjusted with isolation solution and centrifuged at 100,000 g for 3 h at 4°C. 
Synaptosomes were collected at the 1.25/1.0 M sucrose interface, diluted 1:10 
in cold 0.32 M sucrose with 0.1 mM CaCl2 and pelleted (15,000 g for 30 min at 
4°C). Pellets were resuspended in 1 ml of isolation solution and a small sample 
taken for gel electrophoresis, and this synaptosomal suspension was then 
diluted 1:10 in cold 0.1 mM CaCl2 and an equal volume of 2× concentrated 
solubilization buffer (2% Triton X-100, 40 mM Tris, pH 6.0) was added to the 
suspension. The synaptosomal membranes were then incubated for 30 min on 
ice with mild agitation and the insoluble material (synaptic junctions) pelleted 
(40,000 g for 30 min at 4°C). The supernatant (extrasynaptic fraction) was 
decanted and proteins precipitated with 6 volumes of acetone at -20°C and 
recovered by centrifugation (18,000 g for 30 min at -15°C). The synaptic 
junctions pellet was washed twice in pH 6.0 solubilization buffer, resuspended 
in 5 ml of 1% Triton X-100 and 20 mM Tris (pH 8.0), incubated for 30 min on ice 
with mild agitation, centrifuged (40,000 g for 30 min at 4°C) and the supernatant 
(presynaptic active zone fraction) processed as above. The increase in pH from 
6.0 to 8.0 leads to the dissociation of the extracellular web filaments that 
strongly connect the presynaptic active zone to the postsynaptic density. In this 
way the active zone is solubilized while the postsynaptic density is mostly 
maintained, because the amount of detergent is not sufficient to achieve its 
solubilization (see Phillips et al., 2001). PMSF (1 mM) was added to the 
suspension in all extraction steps to minimize proteolysis. The pellets from the 
supernatants and the final insoluble pellet (postsynaptic density fraction) were 
solubilized in 5% SDS, the protein concentration determined by the BCA 
method. 
 
Material and Methods 
  
38 
 
3.2 NEUROCHEMICAL ANALYSIS 
3.2.1 Protein quantification by the bicinchoninic acid (BCA) method 
 
The quantification of protein in the biological samples was performed by 
using the bicinchoninic acid (BCA) method, a colorimetric detergent-compatible 
procedure. In brief, a standard curve was first prepared by diluting BSA with 
milliQ water to several concentrations: 2, 1, 0.5, 0.25, 0.125, 0.0625 and 0 µg/ 
µl. The samples were diluted 1/10 in milliQ water and the buffer previously used 
to lyse the samples was also diluted 1/10. The standard curve was then 
prepared in a 96-multiwell plate by pipetting 25 µl of each concentration of the 
diluted BSA, in triplicate, followed by 25 µl of the diluted lysis buffer in each of 
the wells. The diluted samples in triplicate were prepared in the same way, but 
25 µl of milliQ water were added to each well instead of the diluted lysis buffer. 
Next, the reagent A (containing bicinchoninic acid and tartrate in an alkaline 
carbonate buffer) was mixed with the reagent B (containing 4% copper sulfate 
pentahydrate solution) of the kit in a 50:1 proportion, for 1 min, protected from 
light, thus forming the BCA reagent. After the mixing, 200 µl of the BCA reagent 
were added to each well, the plate was protected from light and placed for 30 
minutes in an incubator at 37ºC. Lastly, the plate was cooled to RT and the 
protein read at 570 nm in a plate reader spectrophotometer. 
 
3.2.2 Western blot 
  
The samples for Western blot analysis were prepared with SDS-PAGE 
sample buffer composed of a 4x Tris.Cl/SDS solution (0.5 M Tris and 0.4% 
SDS, pH 6.8 corrected with HCl and filtered with 0.45 µM pore filters), 30% (v/v) 
glycerol, 0.6 M dithiothreitol (DTT), 10% (w/v) SDS and 0.012% of 3',3",5',5"-
tetrabromophenolsulfonphthalein (bromophenol blue), and the volume adjusted 
with milliQ water to normalize for a maximum of 2 µg/µl. The SDS-PAGE 
sample buffer increased the denaturation of the protein in the samples to a 
primary conformation, assuring a near uniform negative charge and also 
increased the sample density, facilitating gel loading and preventing convective 
migration out of the sample wells. The samples were denaturated by boiling at 
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95ºC for 5 min and separated by SDS-PAGE electrophoresis, using 10% 
polyacrylamide resolving gels and 4% polyacrylamide concentrating (stacking) 
gels (see Table 1), under reducing conditions at 80-120 mV. Prestained 
precision protein standards were run simultaneously with the samples to help 
identify the proteins of interest. The proteins in the gel were then 
electrophoretically transferred (1A current, for 1.5 hours at 4ºC with constant 
agitation) to previously activated polyvinylidene difluoride (PVDF) membranes 
(0.45 μm). After blocking for 1 h at RT with 5% bovine serum albumin (BSA) in 
Tris-buffered saline (Tris 20 mM, NaCl 140 mM, pH 7.6) containing 0.1% Tween 
20 (TBS-T), to prevent nonspecific binding, the membranes were incubated 
overnight at 4°C with the primary antibody diluted in TBS-T with 1% BSA (the 
antibodies and dilutions used are described in Table 2). After three washing 
periods of 15 min with TBS-T, the membranes were incubated with the 
appropriate alkaline phosphatase-tagged secondary antibody (dilution 1:20,000 
or 1:3000 - see table 2) diluted in TBS-T containing 1% BSA, for 2 h at RT. After 
three 15-min washes in TBS-T, the membranes were incubated with Enhanced 
Chemi-Fluorescence (ECF) substrate and visualized in a VersaDoc 3000 
imaging system (Biorad, Amadora, Portugal) with the assistance of Quantity 
one software. When applicable the membranes were then re-probed and tested 
for β-actin immunoreactivity to confirm that similar amounts of protein were 
applied to the gels. 
 
GEL Formulation (1 GEL) 4 % 10 % 
Tris-buffer, 1.5 M, pH 8.8 (resolving gel) - - - - - - - - 2.5 ml 
Tris-buffer, 0.5 M, pH 6.8 (stacking gel) 2.5 ml - - - - - - - - 
Acrylamide 30 %  1.3 ml 3.3 ml 
Ultrapure water 6.1 ml 4.1 ml 
SDS 10 % 100 µl 100  µl 
TEMED 10 µl 5  µl 
APS 10 % (freshly prepared in water) 50 µl 50 µl 
TABLE 1: Gel formulations in Western blot 
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3.2.3 [3H]Dopamine release assays from rat striatal nerve terminals 
 
The experiments were carried out as previously reported (Ferreira et al., 
2009; Martíre et al., 2011). The P2 synaptosomal fraction was diluted to 0.5 mL 
with Krebs-HEPES solution (in mM: NaCl 113, KCl 3, KH2PO4 1.2, MgSO4 1.2, 
CaCl2 2.5, NaHCO3 25, glucose 10, HEPES 15, pH 7.4, 37ºC), containing the 
monoamine oxidase B (MAO-B) inhibitor, pargyline (10 µM). Synaptosomes 
were then incubated for 10 min in the presence of [3H]dopamine (~60 Ci/mmol, 
final concentration, 150 nM). A 16-microvolume chamber superfusion setup was 
filled with the preloaded synaptosomes (see Fig. 3.5), which were trapped by 
layers of Whatman GF/C filters and superfused continuously at a rate of 0.8 
mL/min at 37ºC until the end of the experiment. This system allows testing 
seven pharmacological treatments in duplicate (each averaged as n=1) to 
reduce the number of animals utilized, in accordance with the ARRIVE 
guidelines. After a 10-min washout period, nine 2-min samples were collected 
for liquid scintillation assay.  
The radioactivity content of each sample and of the filters with the trapped 
synaptosomes was counted by a Tricarb β-counter (PerkinElmer, Waltham, 
Massachusetts, USA). Disintegrations per minute (DPM) values were 
expressed as fractional release (FR%), i.e. the percent of actual content in the 
effluent as a function of the total synaptosomal content of radioactivity.  
After collecting four 2-min samples as a baseline, nicotine and adenosine 
receptor ligands, alone or in combination, were applied through the superfusion 
solution. nAChR antagonists were present since the beginning of the 10-min 
washout period, until the end of the experiment.  
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3.2.3.1 Calculations and statistics for [3H]dopamine release assays 
 
In each individual experiment various treatments were performed, 
including paired vehicle controls and various pairs of treatments with ligands 
alone or in combination.  To obtain the net effect of each tested drug on the 
amount of [3H]dopamine released, the averaged duplicates of the respective 
controls (not shown) were subtracted from the averaged treatment. Application 
of this principle originates the graphs (A-D) pictured in Figure 3.6. In this 
simulated case, where nicotine and an adenosine receptor ligand such as 
CGS21680 are represented to be tested separated and together, the release 
elicited by nicotine alone (corresponding to the area under the curve) (graph A) 
amounts to “X” fractional release % (FR%) and in the same way for CGS21680 
the value “Y” FR% is obtained (graph B). The combination of 
Figure 3.5 - Images of the superfusion setup illustrating steps in the 
[3H]dopamine release assays from rat striatal nerve terminals (synaptosomes).  
Synaptosomes were incubated for 10 min at 37ºC in the presence of [3H]dopamine, 
after which they were trapped by layers of Whatman GF/C filters, in microvolume 
chambers, and superfused continuously at a rate of 0.8 mL/min at 37ºC until the end of 
the experiment. 2-min samples were collected for liquid scintillation assay. 
loaded into the setup trapped by filters 
continuously superfused
synaptosomes
incubated with
[3H]dopamine 
effluent collected liquid scintillation assay 
incubation with drugs
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nicotine+CGS21680 yields a total value of area under the curve of “V” FR% 
(graph C). Relevantly, the “V” value is understood as the sum of “Y”+”Z” (graph 
D), where “Z” is the modified effect of nicotine, after discounting the effect of 
CGS21680 per se (area “Y” in graph D). In the [3H]dopamine release essays 
presented in this thesis, the data corresponding in Figure 3.6 to “X”, “Y” and “V” 
were used for the following comparisons:  “X”, “Y” and “V” were compared to 
zero FR% (i.e no effect on dopamine release) and if statistical difference was 
detected the graphs were marked with *, ** or ***, depending on the value of 
statistical significance. Furthermore, “X” was also compared to “Z” to assess 
whether CGS21680 (or any other adenosinergic ligand alone or in combination) 
altered the effect of nicotine. In these cases, if statistical difference was 
detected the graphs were marked with $, $$ or $$$.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 - An explanatory figure for the 
calculations of [3H]dopamine release 
assays. In this scenario, modelled release 
curves are displayed for a hypothetical drug 
effect alone, e.g. nicotine (A) or CGS21680 (B) 
and in combination (e.g. CGS21680+nicotine) 
(C). For instance, if nicotine (A) and an 
adenosine receptor ligand such as CGS21680 
(B) are tested separated and together (C), the 
release from untreated synaptosomes (vehicle 
control) is subtracted from the release in the 
presence of CGS21680 alone and of nicotine 
alone, and the release in the presence of 
CGS21680 alone is also subtracted from the 
release in the combined presence of 
CGS21680 plus nicotine (C and D). “X” 
represents the release induced by nicotine; “Y” 
represents the release induced by CGS21680 
per se; “V” represents the release induced by 
nicotine+CGS21680 (“Y”+”Z”) where “Z” is the 
release corresponding to  the modified effect 
of nicotine, after discounting the effect of 
CGS21680 per se (“Y”). 
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3.2.4 Adenosine release from rat striatal synaptosomes 
 
Adenosine release was assayed both in batch-like conditions as well as 
upon superfusion of synaptosomes. In batch-like conditions, striatal 
synaptosomes (~1.2 mg protein × mL-1) were incubated at 37ºC for 15 min in 
the presence of the adenosine deaminase inhibitor, EHNA (20 µM). Half of the 
synaptosomal samples were challenged with nicotine (1 µM) for 8 min at 37ºC 
and the other half served as control. The mixtures were then centrifuged, at 
14000 g for 10 min at 4ºC, and the supernatant was used for high-performance 
liquid chromatograph (HPLC) analysis (see below), in duplicate. In superfusion 
conditions, the synaptosomes were superfused for 15 min in a manner similar to 
the [3H]dopamine release assay. The synaptosomes were then exposed during 
5 min to EHNA (20 µM) or EHNA combined with nicotine (30 nM or 1 µM), and 
the effluents were collected for HPLC analysis. 
The separation and quantification of adenosine and its metabolites was 
carried out by HPLC, as previously described (Cunha and Sebastião, 1993), 
employing a LiChroCart-RT 125-4 C-18 reverse-phase column (particle size, 5 
µm), combined with an UV detector set to 254 nm. The mobile phase consisted 
of KH2PO4 (100 mM) and methanol (85/15 v/v%) at pH 6.50, with the flow rate 
of 1 mL × min-1, and a loop volume of 50 µL. The identification and 
quantification of adenosine and its metabolites was achieved by calculating the 
peak areas then converted to concentration values (expressed as µmol × mg 
protein-1) by calibration with known adenosine standards ranging from 0.1 to 10 
µM. 
 
3.3 RAT LOCOMOTOR BEHAVIOURAL ANALYSIS: NICOTINE 
SENSITIZATION 
 
During behaviour test periods adult male Wistar rats (10-14 weeks old) 
were maintained in a room under controlled temperature (23±2 ºC) subject to a 
12 h light/dark cycle (lights on 7.00 a.m.) with free access to food and water. All 
manipulations were carried out between 9:00 a.m. and 6:00 p.m. to avoid 
influences from circadian rhythms. The behavioural test was performed in a 
sound-attenuated room with low-intensity light maintained constant during the 
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Figure 3.7 – Image of the open-field 
arena during the behavioural test. A 
Wistar rat is present in the apparatus. 
testing period. During the tests, the experimenter stayed in a room adjacent to 
the one where the test was performed. To remove the odor traces left by the 
previous animal the floor and walls of the equipment were cleaned with 10 % 
ethanol before testing the next animal. 
 
3.3.1 Open field test 
 
The open field is a well-established 
test to measure locomotor activity in 
rodents, among other behavioural 
responses (Walsh and Cummins, 1976; 
Prut and Belzung, 2003).  
Locomotor behaviour was 
monitored in a square open field arena, 
with 100X100 cm and 60 cm height, 
made of dark grey PVC plastic (Fig. 
3.7). The locomotor activity of the rats 
was evaluated by measuring the total 
distance traveled over a period of 30 
min. Analysis of the data was performed using the Any-maze video tracking 
software. 
 
3.3.2 Drug administration 
 
The nicotine solution was prepared fresh each day by dissolving nicotine 
bitartrate in an isotonic saline solution (0.9% NaCl) neutralized to pH 7.2. 
ZM241385 was dissolved in a saline solution with 5% DMSO. Nicotine (0.5 
mg/kg, as nicotine-tartrate salt) or saline were injected subcutaneously (s.c.) in 
a volume of 1 mL/kg of body weight immediately before the test period, whereas 
ZM241385 (1 mg/kg) or vehicle solution were administered intraperitoneally 
(i.p.) 30 min before the test period. The dose of each drug was chosen based 
on previous studies in rats showing the induction of a robust and long-lasting 
locomotor sensitization by nicotine (Schoffelmeer et al., 2002; Le Foll et al., 
Material and Methods 
 
45 
 
2003; Kayir et al., 2009) and the efficient antagonism of A2ARs by ZM241385 
(Poucher et al., 1996; Prediger and Takahashi, 2005; Montandon et al., 2008), 
at the current doses used. Non-water soluble materials were dissolved in 
DMSO, and further diluted in H2O, aliquoted and kept at -20ºC until use. 
 
3.3.3 Experimental procedures 
 
The nicotine-induced locomotor sensitization was assessed based on 
previous reports (Werling et al., 2009; Wellman et al., 2011). For this assay, the 
rats were randomly divided into four experimental groups. On the first two days, 
all the rats were adapted to the open field arena for 30 min each day 
(habituation). For the next eight consecutive days, all rats received two daily 
injections before the test period. ZM241385 or its vehicle (0.9% saline plus 5% 
DMSO), was injected 30 min before the test, while nicotine or its vehicle (0.9% 
saline) 30 min later, immediately before the behavioural test. The rats were 
grouped based on the following injection scheme: vehicle-vehicle (n=3), vehicle-
nicotine (n=4), ZM241385-vehicle (n=4) and ZM241385-nicotine (n=5). 
Following the 8 day-test period, the rats from all groups remained drug-
free for seven consecutive days. On drug-free day 8, all rats were injected with 
nicotine (0.5 mg/kg) and immediately placed in the open field arena (challenge 
day) (see Fig. 3.8). 
It should be referred that in Figure 4.14 (Results section) the same set of 
symbols (* and $) is used on the graph corresponding to the locomotor activity 
assay, instead of dopamine release. 
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3.4 MATERIALS 
3.4.1. Chemicals 
 
Phenylmethanesulfonyl fluoride (PMSF), DL-dithiothreitol (DTT), protease 
inhibitor cocktail (leupeptin, pepstatin A, chymostatin and antipain), 2-bromo-2-
chloro-1,1,1-trifluoroethane (halothane), pargyline, bovine serum albumin 
(BSA), (-)-nicotine hydrogen tartrate salt and Whatman GF/C filters were 
obtained from Sigma (Sintra, Portugal). Sodium dodecyl sulphate (SDS) and the 
Quantity one software were from Bio-Rad (Amadora, Portugal). Polyvinylidene 
difluoride (PVDF) membranes, prestained precision protein standards and 
enhanced chemifluorescence substrate (ECF) were purchased from Amersham 
Biosciences (Amadora, Portugal). Bicinchoninic acid (BCA) protein assay 
reagents were from Thermo Scientific (Pierce Biotechnology, Rockford, IL, 
USA). 3,4-[ring-2,5,6-3H] dihydroxyphenylethylamine ([3H]DA) was from 
American Radiolabeled Chemicals, Inc, (St. Louis, MO, USA). α-bungarotoxin, 
α-conotoxin-PIA, dihydro-β-erythroidine, 2-[p-(2-carboxyethyl)phenethylamino]-
5´-N-ethylcarboxamido adenosine (CGS21680), erythro-9-(2-hydroxy-3-
nonyl)adenine hydrochloride (EHNA) and N-(4-cyanophenyl)-2-[4-(2,3,6,7-
tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide (MRS1754) 
1 2 3 10 18
habituation sensitization drug free challenge
days of experiment
(8 days injection) (8 days withdrawal)
NO TEST
TEST 
DAY
Figure 3.8 - Timeline of the experimental procedure: nicotine sensitization. The 
rats were first adapted to the open field arena in the first two days (habituation) and 
then daily injected and tested for the next eight consecutive days (sensitization). After 
the eight day test period the rats received no treatment and no test was performed, for 
the next eight days (drug free). On the eighth day of withdrawal (day 18 of experiment) 
all the rats were injected with nicotine and tested in the open field (challenge). 
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Table 2: Primary and secondary antibodies for Western blot 
 
Antibodies Supplier Host Type Dilution 
α7 Abcam rat IgG1 1:3 000 
α4 Abcam rabbit IgG 1:3 000 
α6 Merck 
Millipore 
rabbit N/A 1:3 000 
β2 Merck 
Millipore 
rabbit N/A 1:15 000 
SNAP 25 Sigma mouse IgG1 1:60 000 
Synaptophysin Sigma rabbit IgG1 1:60 000 
Syntaxin Sigma mouse IgG1 1:60 000 
PSD 95 Sigma mouse IgG2a 1:100 000 
β-Actin Sigma mouse IgG2a 1:100 000 
Rabbit 
 alkaline phosphatase 
conjugate  
(AP) 
GE 
Healthcare 
 
goat 
 
IgG 
(H+L) 
 
1:20 000 
Mouse AP GE 
Healthcare 
goat IgG+IgM 
(H+L) 
1:20 000 
Rat AP Santa Cruz chicken IgG 1:3 000 
 Table 2: Primary and secondary antibodies for Western blot 
were from Tocris Bioscience (Bristol, UK) and 4-(2-[7-amino-2-(2-
furyl)]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) was from 
Abcam Biochemicals (Cambridge, UK). Any-maze was from Stoelting (IL, USA). 
Other general reagents, such as salts, were obtained from Sigma (Sintra, 
Portugal).  
 
 3.4.2 Antibodies 
 
All the primary and secondary antibodies used during the studies 
presented are described in table 2.  
 
 
 
 
 
Antibodies Supplier Host Type Dilution 
α7 Abcam ra IgG1 1:3000 
α4 Abcam rabbit IgG 1:3000 
 
α6 
Merck Millipore rabbit N/A 1:3000 
Abcam rabbit IgG 1:600 
β2 Merck Millipore ra bit N/A 1:150  
SNAP 25 Sigma mouse IgG1 1:60000 
Synaptophysin Sigma rabbit IgG1 1:60000 
Syntaxin Sigma mouse IgG1 1:60000 
PSD 95 Sigma mouse IgG2a 1:100000 
β-Actin Sigma mouse IgG2a 1:100000 
Rabbit 
 alkaline 
phosphatase 
conjugate  
(AP) 
 
GE Healthcare 
 
goat 
 
IgG 
(H+L) 
 
1:20000 
Mouse AP GE Healthcare goat IgG+IgM 
(H+L) 
1:20000 
Rat AP Santa Cruz chicken IgG 1:3000 
Table 2: Primary and secondary antibodies for Western blot 
 
 
Table 2: Primary and secondary antibodies for Western blot 
 
Table 2: Primary and secondary antibodies for Western blot 
 
 
Table 2: Primary and secondary antibodies for Western blot 
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3.5 DATA PRESENTATION 
 
All data are expressed as means ± SEM of the indicated number of 
independent observations (n). Raw effect data from release and sensitization 
experiments were normalized to the respective vehicle control except when 
noted. Normalized data were tested for normality by the Kolmogorov-Smirnov 
normality tests and statistical significance was calculated by one-sample t-test 
against a hypothetical value of 100 or 0 (when normalized). If more than two 
groups were compared, one-way ANOVA with Dunett’s post-hoc test was 
performed. Data from paired experiments were compared with the pairwise 
version of the above mentioned tests, and a value of p < 0.05 was accepted as 
a significant difference. 
  
 
 
 
 
4. Results 
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Figure 4.1 – Schematic representation of a 
synapse detailing the localization of nAChRs in 
the neuronal membrane, at presynaptic, 
postsynaptic and extrasynaptic sites. 
Presynaptic
Postsynaptic
Extrasynaptic
Postsynaptic neuron
(dendrite)
Presynaptic neuron
4.1 SYNAPTIC AND SUBSYNAPTIC LOCALIZATION OF NICOTINIC 
RECEPTOR SUBUNITS IN RODENT STRIATUM  
 
It has become increasingly clear that one of the main functions that 
nicotinic acetylcholine receptors (nAChRs) play in the striatum is the modulation 
of neurotransmitter release. The activation of presynaptic striatal nAChRs was 
clearly shown to be able to induce the release of dopamine, among other 
neurotransmitters, in rats and mice (Wonnacott et al., 2000; Salminen et al., 
2004; Exley and Cragg, 2008). However, it is still not clearly known if particular 
nAChR subtypes are predominant in the nerve terminals, and if so, what is their 
relative distribution at different subsynaptic sites, such as the pre- post- and 
extra-synaptic zones (see Fig. 4.1).  The present study aimed to determine if 
some relevant subunits of 
nAChRs, such as α7, α4, α6 and 
β2, were present in the terminals 
of striatal neurons and describe 
the localization and density of 
these subunits at the subsynaptic 
level. To address these objectives 
we used striatal synaptic and sub-
synaptic fractions obtained from 
rodents and gauged the density of 
nAChR subunits by immunoblot 
using commercially available 
antibodies against these proteins. It was also our goal to asses if the distribution 
of the nAChR subunits is similar in Wistar rats and C57BL/6 mice, two animal 
models extensively used in neuroscience research (see Takahashi et al., 2008; 
Blandini and Armentero, 2012). This detailed mapping of the nAChR subunits 
provided insights about the putative involvement of the different nAChR 
subtypes in the release of neurotransmitters, in particular of dopamine, and also 
in postsynaptic signal reception in the striatum (Windels and Kiyatkin, 2003; 
Hamada et al., 2004). Apart from its intrinsic general relevance this data helped 
set the stage for the subsequent work exploring the interaction between 
nAChRs and adenosine A2ARs.   
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4.1.1 Synaptic and subsynaptic levels of nAChRs in the striatum of 
Wistar rats and C57BL/6 mice 
 
The synaptic and subsynaptic levels of α7, α6, α4 and β2 subunits of 
nAChRs were evaluated in the striatum of male adult Wistar rats and C57BL/6 
mice. The synaptic densities of these subunits were determined in 
synaptosomes (membranes from resealed nerve terminals) by Western blot, in 
which were applied three different concentrations of protein of synaptosomes to 
ensure that the signal was not saturated, obtained from the same preparation. 
We confirmed that the synaptosomal membrane preparations indeed 
corresponded to isolated nerve terminals by analyzing the immunoreactivity of 
synaptophysin, a synaptic protein (not shown). To investigate the subsynaptic 
distribution of the nAChR subunits we employed a fractionation method that 
achieves an efficient separation of the pre-, post- and extra-synaptic regions. 
The immunoreactivity of different subunits was evaluated by Western blot in the 
fractions enriched in the presynaptic active zone (PRE), postsynaptic density 
(POST) and areas outside the active zone (EXTRA) and in the initial 
synaptosomal fraction (SYN) (Fig. 4.2). This fractionation technique facilitates 
the access of the antibodies to epitopes located in the synapse, that otherwise 
could be prevented by the proteic matrix that keeps the synapse together (see 
Phillips et al., 2001). It also has the possible advantage of concentrating in the 
samples receptors which have low abundance. The validation of the 
subsynaptic fractionation procedures was performed by quantifying the 
immunoreactivity of specific protein synaptic markers: i) SNAP-25 and syntaxin 
in the presynaptic active zone fraction, ii) PSD-95 in the postsynaptic density 
fraction and iii) synaptophysin (a synaptic vesicles protein) in the extrasynaptic 
fraction. As can be seen in Figure 4.2 A and B, the presynaptic fraction 
displayed higher levels of SNAP-25 and syntaxin as compared with the post- or 
extra-synaptic fractions, whereas the postsynaptic fraction exhibited higher 
levels of PSD-95, being this protein almost undetectable in the other 
subsynaptic fractions. The density of synaptophysin was higher in extrasynaptic 
than in presynaptic fractions, and it was almost inexistent in the postsynaptic 
density. The labeling of synaptophysin observed in the presynaptic fraction is 
possibly due, at least partially, to the presence of docked synaptic vesicles 
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(Pinheiro et al., 2003). These data allow assessing the efficiency of separation 
of the subsynaptic fractions used in this study.  
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Figure 4.2 – Assessment of the efficiency of separation of the PRE-, POST- and EXTRA-
synaptic fractions of rat and mouse striatum nerve terminals. The purity of the fractions 
enriched in the presynaptic active zone (PRE), postsynaptic density (POST) and areas outside 
the active zone (EXTRA) and in the initial synaptosomal fraction (SYN) was gauged in Wistar 
rats (A) and C57BL/6 mice (B) by the segregation of the active zone markers (SNAP-25 and 
syntaxin), postsynaptic density marker (PSD-95) and of the marker exterior (vesicular) to the 
active zone (synaptophysin). Representative Western blot images displaying the subsynaptic 
densities of the markers are shown. The analysis of each marker was performed in different blot 
gels with samples from each of the fractions from the same fractionation using 10 µg of each 
fraction per gel. The percentage of immunoreactivity was obtained taking as reference the total 
value of reactivity in each separate experiment. Graphs exhibit the mean ± SEM of 3-4 
experiments derived from separate fractionations.  
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4.1.1.1 nAChRs α7 subunit synaptic and subsynaptic levels 
 
By Western blot analysis it was found that the α7 subunit of nAChRs was 
localized in Wistar rats and in C57BL/6 mice striatal synaptic membranes, as 
displayed by the specific bands of three different concentrations of protein. The 
antibody recognized bands of identical molecular weight (63 kDa), in rats (n = 3) 
and mice (n = 4). Immunoreactivity increased with higher amounts of loaded 
protein, assuring the signal was not saturated (Fig. 4.3 A and B).  
As showed in Figure 4.3 C, in rat striatum the α7 subunit was localized 
mainly at the presynaptic active zone (51.5 ± 4.4% of total immunoreactivity, n = 
3) and was also present in extrasynaptic locations, outside the active zone (36.7 
± 3.3% of total immunoreactivity, n = 3), but it had a much smaller presence in 
the postsynaptic density (11.8 ± 2.7 % of total immunoreactivity, n = 3). In 
subsynaptic fractions isolated from the striatum of mice, it was observed that 
the α7 subunit (Fig. 4.3 D) was localized mainly at the presynaptic active zone 
(63.6 ± 6.1 % of total immunoreactivity, n = 4), similarly to what was observed in 
rat striatum. It was also identified in the postsynaptic density (24.5 ± 5.6 % of 
total immunoreactivity, n = 4) and had a smaller presence outside the active 
zone (11.9 ± 1.6 % of total immunoreactivity, n = 4). 
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Figure 4.3 - Synaptic and subsynaptic distribution of the α7 subunit of nAChRs in the 
striatum of Wistar rats and C57BL/6 mice. (A and B) Levels of α7 subunits of nAChRs in 
membranes of isolated nerve terminals (synaptosomes), from the striatum of adult male rats (A) 
and mice (B). The graphs represent the percentage of α7 immunoreactivity for different 
amounts of loaded protein, taking as reference the maximum value of immunoreactivity in each 
blot. The data are the means ± SEM of 3-4 independent experiments. Representative Western 
blots, where 3 different protein amounts (20, 40 and 50 µg) of synaptosomes were applied, are 
shown. (C and D) Graphs and representative Western blots show the subsynaptic levels of α7 
subunits of nAChRs in striatum of rats (C) and of mice (D). The α7 immunoreactivity was 
compared after fractionation of striatal total nerve terminals (synaptosomes, SYN) into fractions 
enriched in the presynaptic active zone (PRE), postsynaptic density (POST) and areas outside 
the active zone (EXTRA). The amount of loaded protein for each fraction was 20 µg and the 
fraction corresponding to total synaptosomes was used as an internal control. The percentage 
of immunoreactivity of the subunits was obtained taking as reference the total value of reactivity 
in each separate experiment. Graphs exhibit the means ± SEM of 3-4 independent experiments 
derived from three or four fractionations from different groups of 5-8 rats or 10-12 mice.  
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4.1.1.2 nAChRs β2 subunit synaptic and subsynaptic levels 
 
The signal for the β2 subunit in Wistar rats and C57BL/6 mice was 
identified in synaptic membranes by Western blot, showing the localization of 
the subunit in striatal nerve terminals (Fig. 4.4 A and B). The antibody 
recognized bands of identical molecular weight (55 kDa), in rats (n = 3) and 
mice (n = 3). Immunoreactivity increased with higher amounts of loaded protein. 
The results obtained showed that the striatal subsynaptic localization of 
the β2 subunit in Wistar rats was predominantly in extrasynaptic sites, outside 
the active zone (Fig 4.4 C) (86.1 ± 2.5 % of total immunoreactivity, n = 3), and 
that it had a significantly lower density in the presynaptic active zone (9.6 ± 1.4 
% of total immunoreactivity, n = 3). The immunoreactivity of this subunit was 
less abundant in the postsynaptic enriched fraction (4.4 ± 2.6 % of total 
immunoreactivity, n = 3). In C57BL/6 mice (Fig. 4.4 D) the β2 subunit was 
localized mainly at the presynaptic active zone (51.8 ± 12.3 % of total 
immunoreactivity, n = 3) and also had a strong component in extrasynaptic sites 
(47.4 ± 12.5 % of total immunoreactivity, n = 3). It showed a negligible presence 
in the postsynaptic density (2.5 ± 0.03 % of total immunoreactivity, n = 3). 
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Figure 4.4 - Synaptic and subsynaptic distribution of the β2 subunit of nAChRs in the 
striatum of Wistar rats and C57BL/6 mice. (A and B) Levels of the β2 subunit of nAChRs in 
membranes of isolated nerve terminals (synaptosomes), from the striatum of adult male rats (A) 
and mice (B). The graphs represent the percentage of β2 immunoreactivity for different 
amounts of loaded protein, taking as reference the maximum value of immunoreactivity in each 
blot. The data are the means ± SEM of 3 independent experiments. Representative Western 
blots, where 3 different protein amounts (20, 40 and 50 µg) of synaptosomes were applied, are 
shown. (C and D) Graphs and representative Western blots show the subsynaptic levels of the 
β2 subunit of nAChRs in striatum of rats (C) and of mice (D). The β2 immunoreactivity was 
compared after fractionation of striatal total nerve terminals (synaptosomes, SYN) into fractions 
enriched in the presynaptic active zone (PRE), postsynaptic density (POST) and areas outside 
the active zone (EXTRA). The amount of loaded protein for each fraction was 20 µg. The 
percentage of immunoreactivity of the subunits was obtained taking as reference the total value 
of reactivity in each separate experiment. Graphs exhibit the mean ± SEM of 3 experiments 
derived from three fractionations from different groups of 5-8 male Wistar rats or 10-12 C57BL/6 
mice.  
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4.1.1.3 nAChRs α4 subunit synaptic and subsynaptic levels 
 
Results for the α4 subunit showed its localization in striatal synaptic 
membranes of rats (n = 3) and mice (n = 4), evaluated by Western blot (Fig. 4.5 
A and B). The density of the α4 subunit increased when progressively higher 
amounts of protein were loaded. The antibody recognized bands of identical 
molecular weight (60 kDa) in rats and mice. 
In rat striatum the α4 subunit was localized predominantly in extrasynaptic 
sites, outside the active zone (88.8 ± 9.5 % of total immunoreactivity, n = 3), 
and had a significantly lower density in the presynaptic active zone (10.8 ± 9.3 
% of total immunoreactivity, n = 3). The immunoreactivity of this subunit was 
lowest in the postsynaptic enriched fraction (0.5 ± 0.2 % of total 
immunoreactivity, n = 3) (Fig. 4.5 C). In C57BL/6 mice the α4 subunit (Fig. 4.5 
D) was mostly located at the presynaptic active zone (69.1 ± 5.7 % of total 
immunoreactivity, n = 4) and had a significant presence in extrasynaptic sites 
(30.6 ± 5.6 % of total immunoreactivity, n = 4). In the postsynaptic density the 
level of α4 subunit was almost null (0.4 ± 0.4 % of total immunoreactivity, n = 4). 
 
As can be seen in Figures 4.4 (C and D) and 4.5 (C and D) the α4 and β2 
subunits displayed a similar subsynaptic distribution, which is in agreement with 
the notion that these subunits together form abundant heteromeric nAChRs 
(see Whiting et al., 1987; Flores et al., 1992). Interestingly, there is a significant 
difference between animal species, since in samples obtained from Wistar rats 
the α4 and β2 subunits are predominantly localized in extrasynaptic sites (Figs. 
4.4 and 4.5 C) outside the active zone, whereas in C57BL/6 mice the subunits 
are mainly in the presynaptic fraction, at the synaptic active zone (Figs. 4.4 and 
4.5 D). 
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Figure 4.5 - Synaptic and subsynaptic distribution of the α4 subunit of nAChRs in the 
striatum of Wistar rats and C57BL/6 mice. (A and B) Immunoreactivity of the α4 subunit of 
nAChRs in membranes isolated from the striatum of rats (A) and mice (B). The graphs 
represent the percentage of immunoreactivity, for different amounts of loaded protein (20, 40 
and 50 µg), taking as reference the maximum value of immunoreactivity in each blot. The data 
are the means ± SEM of 3-4 independent experiments. Representative Western blots are 
displayed below. (C and D) Graphs and representative Western blots show the subsynaptic 
levels of the α4 subunit of nAChRs in the striatum of rats (C) and mice (D). The α4 
immunoreactivity was compared after fractionation of striatal total nerve terminals 
(synaptosomes, SYN) into fractions enriched in the presynaptic active zone (PRE), postsynaptic 
density (POST) and areas outside the active zone (EXTRA). Loaded protein for each fraction 
was 20 µg. The percentage of immunoreactivity was obtained taking as reference the total 
value of reactivity in each separate experiment. Representative Western blots are displayed 
below. Graphs exhibit the mean ± SEM of 3-4 experiments derived from fractionations from 
different groups of 5-8 rats or 10-12 mice.  
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4.1.1.4 nAChRs α6 subunit synaptic and subsynaptic levels  
 
The α6 subunit was localized in the synaptic membranes from striatum of 
Wistar rats (n = 4) and C57BL/6 mice (n = 3) (Fig. 4.6 A and B). The Western 
blot analysis revealed specific bands of increasing immunoreactivity signal, with 
higher amounts of loaded protein. In rats and mice, the antibody recognized 
bands of identical molecular weight (56 kDa). 
The results obtained for the α6 subunit in the striatum of rats (Fig. 4.6 C) 
revealed that it was clearly predominant in the postsynaptic density (56.4 ± 3.9 
% of total immunoreactivity, n = 3) albeit also being extensively located in 
extrasynaptic sites and in the presynaptic active zone (27.6 ± 1.1 % and 16.0 ± 
5.1 % of total immunoreactivity, respectively, n = 3). Like in the rat, the α6 
subunit was prevalent in the postsynaptic density in mice (4.6 D) (76.8 ± 5.5 % 
of total immunoreactivity, n = 3) albeit also being present in extrasynaptic sites 
and in the presynaptic active zone (16.9 ± 8.5 % and 9.4 ± 1.5 % of total 
immunoreactivity, respectively, n = 3). 
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Figure 4.6 - Synaptic and subsynaptic distribution of the α6 subunit of nAChRs in the 
striatum of Wistar rats and C57BL/6 mice. (A and B) Density of the α6 subunit of nAChRs in 
membranes of purified synaptosomes isolated from the striatum of adult male rats (A) and (B) 
mice. Graphs represent the percentage of immunoreactivity for each quantity of protein taking 
as reference the maximum value of immunoreactivity in each blot and are the means ± SEM of 
3-4 independent experiments. Representative Western blots, where 3 different amounts of 
protein of synaptosomes were applied, are shown below. (C and D) Subsynaptic levels of the 
α6 subunit of nAChRs in striatum of rats (C) and mice (D). The α6 immunoreactivity was 
compared after fractionation of striatal total nerve terminals (synaptosomes, SYN) into fractions 
enriched in the presynaptic active zone (PRE), postsynaptic density (POST) and areas outside 
the active zone (EXTRA). Loaded protein for each fraction was 20 µg. The percentage of 
immunoreactivity was obtained taking as reference the total value of reactivity in each separate 
experiment.  Representative Western blots are shown below. Graphs exhibit the means ± SEM 
of 3 independent experiments derived from three fractionations from different groups of 5-8 rats 
or 10-12 mice.  
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4.2 CHARACTERIZATION OF NICOTINE-INDUCED [3H]DOPAMINE  
RELEASE IN RAT STRIATAL SYNAPTOSOMES - MODULATION BY 
ADENOSINE RECEPTORS 
 
To investigate the purported functional interaction between presynaptic 
nicotinic acetylcholine and adenosine A2A receptors, we used a golden standard 
tool, the synaptosomal preparation, which consists of resealed nerve terminals, 
free from polysynaptic and glial interferences (Raiteri and Raiteri, 2000) (see 
section 3.1.2). Striatal synaptosomes were loaded with tritium-labeled dopamine 
([3H]dopamine), in the presence of the MAO-B inhibitor, pargyline (10 µM), to 
avoid degradation of the dopamine; trapped in filters, superfused and stimulated 
either by nicotine at various concentrations, by adenosine receptors ligands, or 
by a combination of them.  
We performed assays of nicotine-induced [3H]dopamine release using 
synaptosomes from rat and from mouse (not shown), and it was observed that 
in both preparations there was [3H]dopamine release induced by nicotine. 
Considering that the results we obtained from the synaptic and subsynaptic 
localization of the nAChR subunits showed that their striatal distribution was to 
some extent similar in rats and mice; that the studies indicating the presence of 
adenosine A2ARs in striatal dopaminergic terminals were performed in rat (see 
Borycz et al., 2007; Gomes et al., 2006, 2009) and taking into account the 
previous neurotransmitter release studies of our research group (e.g. Köfalvi et 
al., 2007; Ferreira et al., 2009), the following studies were performed using only 
Wistar rats.   
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Figure 4.7 - Nicotine stimulates [3H]dopamine ([3H]DA) release from rat striatal 
synaptosomes. (A) Time course of the averaged release of [3H]DA. Synaptosomes 
were treated with various concentrations of nicotine (1, 30, 300 nM or 3 µM) for 8 min, 
as indicated by the horizontal bar. (B) Concentration-response curve for nicotine to 
trigger the release of [3H]DA. The values of EC50= 68.0 ± 17.2 nM and [Emax]= 6.80 ± 
0.67 FR%; were determined for nicotine. * p<0.001 vs. non-stimulated control; n = 10-
21 independent observations in duplicate. 
 
 
Figure 3.6 - Nicotine stimulates [3H]dopamine ([3H]DA) release from rat striatal 
synaptosomes. (A) Time course of the averaged release of [3H]DA. Synaptosomes 
were treated with various concentrations of nicotine (1, 30, 300 nM or 3 µM) for 8 min, 
as indicated by the horizontal bar. (B) Concentration-response curve for nicotine to 
trigger the release of [3H]DA. The values of .(EC50= 68.0 ± 17.2 nM and [Emax]= 
6.80 ± 0.67 FR; were determined for nicotine. * p<0.001 vs. non-stimulated 
control; n = 10-21 independent observations in duplicate. 
 
4.2.1 Nicotine stimulates the release of [3H]dopamine from rat 
striatal synaptosomes  
 
Nicotine (1, 30, 300 nM and 3 µM) stimulated the release of [3H]dopamine 
([3H]DA) in a concentration-dependent manner (Fig. 4.7 A and B). With this 
dose-response curve it was determined: i) the EC50 (half maximal effective 
concentration) that represents the concentration of the agonist (nicotine) which 
produces 50% of the maximum possible response, indicating the potency of the 
agonist; and ii) the Emax, which represents the maximum possible effect for the 
agonist, describing its efficacy. Thus, for nicotine-induced dopamine release it 
was determined a value of EC50= 68.0 ± 17.2 nM and a Emax= 6.80 ± 0.67 
fractional release (FR%), n = 10-21 rats, in duplicate.  
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4.2.2 Putative involvement of adenosine receptor ligands on the 
release of [3H]dopamine 
 
Given that the major goal of this part of the study was to investigate 
whether nicotine receptors and adenosine receptors act in concert to regulate 
dopamine release in the striatum, we evaluated the effect of A2AR ligands per 
se on the release of [3H]dopamine: the A2AR agonist CGS21680 (30 nM) 
stimulated the release of [3H]DA (0.63 ± 0.25 FR%, n = 10, p < 0.05, t = 2.503, 
df = 9) (Fig. 4.8), while the A2AR antagonist ZM241385 (100 nM) was without 
effect (0.16 ± 0.24 FR%, n = 18, p > 0.5, t = 0.6823, df = 17, Fig. 4.8). Since 
ZM241385 can also antagonize A2BRs (Lasley et al., 2007; Li et al., 2007), 
although with lower potency than A2ARs (Poucher et al., 1995; Ji and Jacobson, 
1999), we also tested the A2BR antagonist MRS1754 (200 nM), which was 
found without effect per se (0.53 ± 0.22 FR%, n = 7, p > 0.05, t = 0.2383, df = 6; 
Fig. 4.8). Interestingly, the combined application of ZM241385 together with 
MRS1754 stimulated the release of [3H]DA (1.61 ± 0.51 FR%, n = 9, p < 0.05, t 
= 3.165, df = 8) (Fig. 4.8), suggesting a cooperative interaction between A2ARs 
and A2BRs similar to that observed in splenocytes (Moriyama and Sitkovsky, 
2010). Additionally, the nonselective adenosine receptor antagonist, caffeine 
(50 µM) also stimulated the release of [3H]DA (0.53 ± 0.13 FR%, n = 38, p < 
0.0001, t = 3.903, df =37) (Fig. 4.8). 
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Figure 4.8 - The adenosine A2AR agonist, CGS21680 (CGS, 30 nM) but neither the 
A2AR antagonist, ZM241385 (ZM, 100 nM) nor the A2BR antagonist, MRS1754 
(MRS, 200 nM) stimulates [3H]DA release from rat striatal synaptosomes. The 
non-selective adenosine receptor antagonist, caffeine (50 µM) also stimulates [3H]DA 
release, which may be explained by the observation that the simultaneous blockade of 
A2ARs and A2BRs by ZM241385 and MRS1754 also facilitated [
3H]DA release. Data 
are mean ± SEM of 7-38 experiments performed in duplicate. * p < 0.05, *** p < 0.01 
vs. 0 FR% (i.e. no change in baseline); n.s., not significant. 
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4.2.3 Nicotine stimulates the release of [3H]dopamine from rat 
striatal synaptosomes in an adenosine A2A receptor-dependent 
manner 
 
In this part of the study we aimed to define the functional interaction 
between nicotinic and adenosine receptors by evaluating the impact of A2ARs 
on modulating the nicotine-stimulated dopamine release in striatal nerve 
terminals. 
In experiments combining A2AR ligands with nicotine, we observed that the 
selective A2AR agonist CGS21680 (30nM) inhibited the effect of nicotine on 
[3H]DA release at the two lowest concentrations of nicotine (1 and 30 nM) (Figs. 
4.9 A, B and E), while it had no significant impact on the effect of higher nicotine 
concentrations (300 nM and 3 µM) (Fig. 4.9 E). In the presence of CGS21680, 
the effect of nicotine (1 nM) was abolished (-0.54 ± 0.28 FR%, n = 8, p < 0.05 
vs. CGS21680 alone), while the effect of nicotine (30 nM) was reduced, by 53.1 
± 11.6% (p < 0.01, t = 4.457, df = 6), to a value of 1.47 ± 0.43 FR%, n = 7. The 
effect of CGS21680 was concentration-dependent (Figs. 4.9 B-F), displaying an 
IC50 of 11.0 ± 6.3 nM (IC50 = half maximal inhibitory concentration; provides a 
measure of the effectiveness of the inhibition) and an Imax of 53.8 ± 7.4% for the 
inhibition of 30 nM nicotine-induced [3H]DA release (Imax = maximum value of 
inhibition) (n = 9-11).  
 
In agreement with the involvement of A2ARs to inhibit the action of nicotine, 
the A2AR antagonist ZM241385 (100 nM), facilitated the action of different 
concentrations of nicotine: at 30 nM by 63.4 ± 10.0%, increased the release to 
3.66 ± 0.22 FR%, n = 7, p < 0.05, t = 3.169, df = 6), at 300 nM by 26.2 ± 7.6% 
(to 6.33 ± 0.44 FR%, n = 8, p < 0.01, t = 3.623, df = 7), and at 3 µM by 26.9 ± 
5.3% (to 8.55 ± 0.58 FR%, n = 6, p <0.01, t = 4.835, df = 5) (Fig. 4.10 B-E); 
whereas  at 1 nM no significant facilitation was observed (Fig. 4.10 A and E).  
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C A 
Figure 4.9 - Adenosine A2AR activation inhibits the nicotine-induced [
3H]DA 
release from rat striatal synaptosomes. (A-D) Time course and (E) bar graph 
displaying the averaged release of [3H]DA induced by various concentrations of 
nicotine alone or in presence of the A2AR agonist, CGS21680 (CGS, 10-100 nM). The 
co-administration of CGS21680 and nicotine occurred as indicated by the horizontal 
bars (treatment). (F) Concentration-response curve for CGS21680 (CGS, 10-100 nM) 
to inhibit the nicotine (30 nM) induced release of [3H]DA. Data are mean ± SEM of 6-18 
experiments performed in duplicate. * p < 0.05, ** p < 0.01 and *** p <0.001 vs. 0 FR% 
(i.e. no change in baseline); $ p < 0.05 and $$ p < 0.01 between nicotine alone and 
with CGS21680; n.s., not significant. 
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Figure 4.10 - Adenosine A2AR blockade increases the nicotine-induced [
3H]DA 
release from rat striatal synaptosomes. (A-D) Time courses and (E) bar graph 
displaying the averaged release of [3H]DA induced by nicotine alone (1, 30, 300 nM 
and 3 µM) or in the presence of the A2AR antagonist, ZM241385 (100 nM). The co-
administration of ZM241385 and nicotine occurred as indicated by the horizontal bar 
(treatment). Data are mean ± SEM of 6 experiments performed in duplicate. * p < 0.05 
vs. 0 FR% (i.e. no change in baseline); $ p < 0.05 and $$ p < 0.01 between the 
indicated bars, when compared  to control (nicotine in the absence of any adenosine 
receptor antagonist, displayed in the left bars). 
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Considering that caffeine, a major component of beverages such as coffee 
and tea, is the most widely consumed psychoactive drug worldwide (Fredholm 
et al., 1999) and has been correlated with the incidence of brain pathologies, 
such as PD, we next tested the impact of caffeine on nicotine-induced [3H]DA 
release. The acute administration of 10 µM (data not shown) and 50 µM of 
caffeine failed to facilitate the action of nicotine at lower concentrations (30 and 
300 nM) and actually diminished the effect caused by a higher concentration of 
3 µM nicotine (to 4.06 ± 0.73 FR%, n = 8, p < 0.01, t = 3.795, df = 7) (Fig. 4.11 
A). Since caffeine (Fredholm et al., 1999) as well as ZM241385 have also been 
reported to antagonize the A2BRs of rat and human (Lasley et al., 2007; Li et al., 
2007) albeit with a lower potency than A2ARs (Poucher et al., 1995; Ji and 
Jacobson, 1999), we next tested the effects of a selective A2BR antagonist, 
MRS1754, in our assay. MRS1754 (200 nM) antagonized the 30 nM nicotine-
stimulated release of [3H]DA by 58.7 ± 11.3% (0.89 ± 0.24 FR%, n = 6, p < 0.05, 
t = 3.716, df = 5) (Fig. 4.11 B). When combined with ZM241385, the two 
antagonists (MRS1754 and ZM241385) did not alter the 30 nM nicotine-induced 
release of dopamine (1.33 ± 0.89 FR%, n = 7, p > 0.05 vs. nicotine alone; Fig. 
4.11 B). These results indicated that the facilitation of nicotine's action by 
ZM241385 was not mediated by A2BRs antagonism, although it appears that 
A2BRs may also be involved in the control (qualitatively opposite to the role of 
A2ARs) of nicotinic receptor function in dopaminergic terminals of the striatum.  
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Figure 4.11 - Adenosine A2AR blockade by caffeine does not facilitate the 
nicotine-induced [3H]DA release from rat striatal synaptosomes. (A) In a similar 
experimental paradigm to the previous assay, the non-selective adenosine receptor 
antagonist caffeine (50 µM) failed to mimic the action of ZM241385, i.e. to facilitate the 
effect of nicotine. (B) This lack of caffeine effect may be due to the involvement of 
A2BRs, which are also antagonized by caffeine, since the selective A2BR antagonist, 
MRS1754 (200 nM) inhibited the effect of nicotine and prevented the facilitatory action 
of ZM241385 when the two antagonists were combined. Data are mean ± SEM of 6-13 
experiments performed in duplicate. * p < 0.05 and *** p < 0.001 vs. 0 FR% (i.e. no 
change in baseline); $ p < 0.05 and $$ p < 0.01 between the indicated bars in (A) and 
when compared  to control (nicotine in the absence of any adenosine receptor 
antagonist, displayed in the leftmost bar) in (B); n.s., not significant. 
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4.2.4 Blockade of the α6-containing nAChRs abolishes the action of 
A2AR ligands on nicotine-stimulated [
3H]DA release 
 
Our previous studies about the distribution of nAChR subunits α7, α6, α4 
and β2 revealed that they are localized at striatal nerve terminals (section 4.1), 
which is in accordance with previous studies (Kaiser and Wonnacott, 2000; 
Grady et al., 2002, 2007; Zoli et al., 2002; Meyer et al., 2008; Livingstone and 
Wonnacott, 2009). Moreover, all these subunits were identified in the 
presynaptic active zone of the striatal nerve terminals, thus providing insights 
about which nAChR subtypes might underlie the nicotine-stimulated [3H]DA 
release from striatal synaptosomes. The functional relevance of these subunits 
was next probed using nAChRs antagonists tested against the concentration of 
nicotine (30 nM) that was found to be sensitive to both CGS21680 and 
ZM241385 (see Figs 4.9 and 4.10). 
As illustrated in Fig. 4.12 A and C, the antagonist of α7 nAChRs α-
bungarotoxin (α-BTX, 100 nM) (Marchi et al., 2002), failed to significantly affect 
the action of nicotine (30 nM) on [3H]DA release (mean difference, 16.9 ± 
15.1%, p > 0.05 by repeated measures ANOVA with Dunett’s post-hoc test). 
The majority of nicotine binding sites in the brain contains the β2 subunit (Grady 
et al., 2002; Toyohara and Hashimoto, 2010); accordingly, the β2 subunit-
preferring competitive antagonist dihydro-β-erythroidine (DHβE, 10 µM) (Grady 
et al., 2007) prevented the nicotine stimulated [3H]DA release by 88.1 ± 5.0% (n 
= 5, p < 0.001, by repeated measures ANOVA with Dunett’s post-hoc test) (Fig. 
4.12 A and C). The α6-containing nAChR antagonist α-conotoxin PIA, that 
discriminates between the closely related α6 and α3 subunits (α-CTX PIA, 30 
nM) (Azam and McIntosh, 2005), largely inhibited the action of nicotine by 69.8 
± 7.5% (n = 6, p < 0.001, by repeated measures ANOVA with Dunett’s post-hoc 
test) (Fig. 4.12 A and C). This suggests that ~70% of the nicotine (30 nM) 
stimulated [3H]DA release involves the activation of α6β2-containing receptors. 
Upon blockade of α6-containing nAChRs (in the presence of α-CTX PIA, 30 
nM), the nicotine (30 nM)-induced [3H]DA release was no longer affected by 
either CGS21680 (30 nM, n = 9, p > 0.05 vs. α-CTX PIA + nicotine) or 
ZM241385 (100 nM, n = 9, p > 0.05 vs. α-CTX PIA + nicotine) (4.12 B and C). 
Altogether, these data advocate that A2ARs are selectively coupled to the 
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inhibition of α6β2-containing nAChRs in dopaminergic terminals of the rat 
striatum.  
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Figure 4.12 - The adenosine A2AR-mediated inhibition of the nicotine-induced 
[3H]DA release mainly depended on α6β2-containing nAChRs. (A) Time course 
displaying the averaged [3H]DA release, induced by nicotine (30 nM) in the absence or 
in the presence of nAChRs ligands: the α6 subunit antagonist α-conotoxin PIA (α-CTX 
PIA, 30 nM), the α7 subunit antagonist α-bungarotoxin (α-BTX, 100 nM) or the β2 
subunit antagonist dihydro-β-erythroidine (DHβE, 100 nM). (B) Time course displaying 
the averaged [3H]DA release, induced by nicotine (30 nM) in the presence of α-
conotoxin-PIA (α-CTX-PIA or α-CTX, 30 nM), when combined with adenosine 
receptors (ARs) ligands: either the A2AR agonist CGS21680 (CGS, 30 nM) or the A2AR 
antagonist ZM241385 (ZM, 100 nM). (C) Bar graph summarizing the sensitivity of 30 
nM nicotine-stimulated [3H]DA release under the different conditions tested in (A) and 
(B). Data are mean ± SEM of 9 experiments performed in duplicate. * p < 0.05, ** p < 
0.01 and *** p < 0.001 vs. 0 FR% (i.e. no change in baseline); $$$ p < 0.001 between 
nicotine alone (blue bar) and nicotine with antagonists of nicotinic acetylcholine 
receptors; n.s., not significant. Note that neither CGS21680 nor ZM241385 affected the 
non-α6 subunit-containing nAChR-induced release of [3H]DA, suggesting that it is 
these α6 subunit-containing nAChRs that are modulated by A2ARs to control striatal 
dopamine release. 
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4.3 EVALUATION OF ADENOSINE RELEASE BY STRIATAL 
SYNAPTOSOMES IN THE ABSENCE OR PRESENCE OF NICOTINE 
 
The fact that A2AR and A2BR antagonists modify dopamine release implies 
the existence of endogenous adenosine presumably released from the 
synaptosomes both tonically and upon nAChR activation. To evaluate this 
hypothesis, we directly quantified the levels of adenosine in incubated (batch 
conditions) or superfused synaptosomes. Fig. 4.13 A shows that adenosine and 
its metabolites (inosine and hypoxanthine) were present in concentrations of 6 
nmol/mg protein in incubated synaptosomes (n = 4) whereas their levels were 
below the limit of detection in the superfusate (n = 4; figure not shown). 
Additionally, we found that nicotine 1 µM (and 30 nM, not shown) failed to 
modify the extracellular levels of adenosine or its metabolites either in incubated 
or in superfused synaptosomes (n = 4, p> 0.05) (Fig. 4.13 A and B).  
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Figure 4.13 - HPLC analysis reveals that striatal synaptosomes release 
adenosine. (A) Representative chromatograms and (B) mean ± SEM values for the 
quantified extracellular levels of adenosine and its metabolites in the presence of the 
adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride 
(EHNA) (20 µM), upon incubation of synaptosomes (~1.2 mg protein/ml) in the 
absence or in the presence of nicotine (1 µM); similar results were obtained with 30 
nM nicotine (not shown). Data are mean ± SEM of 4 experiments; n.s., not significant. 
 
 
Figure 3.11 - HPLC analysis reveals that striatal synaptosomes release 
adenosine. (A) Mean chromatograms and (B) mean ± SEM values for the quantified 
extracellular levels of adenosine and its metabolites in the presence of the adenosine 
deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA) (20 
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4.4 NICOTINE-INDUCED MOTOR SENSITIZATION IS FACILITATED 
BY IN VIVO A2AR BLOCKADE 
 
The interplay between nAChRs and A2ARs controlling dopamine release 
from striatal nerve terminals prompted us to test the in vivo relevance of this 
A2ARs-α6β2-containing nAChRs interaction. One simple measure of nicotine 
action is its ability to induce hyperlocomotion (Grottick et al., 2000), which can 
be rated using the open field test (Walsh and Cummins, 1976; Prut and 
Belzung, 2003). 
Before the test period the rats were adapted to the room were the assays 
were performed and to the open field arena, to insure that the novelty of the 
environment did not influence the test results. To that effect, the rats were 
placed in the open field arena for 30 min, in the first two consecutive days of 
experiment (habituation). After the two days of habituation to the apparatus, the 
rats were daily injected with the drugs (or vehicles) and tested for locomotor 
activity in the open field for 30 min, for eight consecutive days (sensitization), 
after which they remained in withdrawal (drug-free) for the following eight days. 
On day 8 of the drug-free period (day 18 of the experiment) all the rats received 
a single injection of nicotine and were tested in the open field (challenge), to 
assess the development of sensitization.  
In the test period, one daily injection of nicotine (0.5 mg/kg of animal body 
weight), significantly (p < 0.05) enhanced locomotor activity (i.e. sensitization) at 
the 7th day, as compared to control rats (i.e. vehicle-vehicle-treated) (Fig. 4.14). 
However, the nicotine-induced sensitization was blunted by the subsequent 
drug-free period (withdrawal) (Fig. 4.14), as indicated by similar locomotor 
activity between nicotine-vehicle and vehicle-vehicle-treated groups (n = 4, p > 
0.05) in the challenge day. The ZM241385 dose used (1 mg/kg of animal 
weight) did not significantly alter per se the locomotor activity of the animals 
(Fig. 4.14) since it remained similar to the locomotor activity of control animals 
throughout the duration of the experiment. Remarkably, ZM241385-pretreated 
rats developed a sensitization to nicotine already at day 2 of injection, which 
was no longer blunted by nicotine withdrawal in the drug-free period (n = 5, p < 
0.05), i.e. locomotor activity of the ZM241385-pretreated rats remained higher 
Results 
 
75 
 
until the challenge day when compared to the ZM241385-vehicle group (Fig. 
4.14).  
Therefore, the results obtained showed that treatment with an antagonist 
of the A2A adenosine receptors (ZM241385) enhanced the locomotor 
sensitization to nicotine, and this sensitization was maintained even after a 
period of several days of drug abstinence, reinforcing the contention for a 
functional interaction between the nAChRs and the A2ARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 - Adenosine A2AR blockade in vivo facilitates the sensitization to 
nicotine stimulated hyperlocomotion. Sixteen rats were used to create factorial × 
groups for vehicle-vehicle, ZM241385-vehicle, vehicle-nicotine and ZM241385-nicotine 
injections. The A2AR antagonist ZM241385 (1 mg/kg) or its vehicle was injected 30 min 
before the test, while nicotine (0.5 mg/kg) or its vehicle was injected immediately before 
the test. After the first two days of 30 min habituation to the open field arena each day, 
the rats received daily injections for 8 days. Significant sensitization to nicotine 
developed on day 7, which was blunted by the subsequent week of abstinence, as 
determined by a single injection of nicotine (challenge) on the day 8 of abstinence (last 
day of the experiment), resulting in no statistically significant difference between the 
vehicle-vehicle group (to which all data points were normalized, represented by the 
dashed line) and the nicotine-vehicle group, represented by the red circle, at day 18 of 
the experiment. ZM241385 had no or a minimal hypolocomotor effect throughout the 
duration of the experiment (green triangles). However, ZM241385-injected rats 
developed sensitization to nicotine already on day 2 (blue diamonds), which was not 
blunted by the drug-free period, as indicated by a statistically significant difference 
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between the ZM241385-vehicle group (green upside-down triangles) and the 
ZM241385-nicotine group (blue diamonds) at day 18 of the experiment. Data are 
mean ± SEM of distance traveled during each 30 min of open field observation. A *p < 
0.05 representing statistical differences between the nicotine injected (red circles) or 
ZM241385-injected (green triangles) and the vehicle-injected (dashed line) rats; and 
$
p 
< 0.05 representing statistical differences between the ZM241385-injected and the 
ZM241385+nicotine-injected rats (blue diamonds), as determined with ANOVA of 
repeated measures and Dunett’s post-hoc analysis. 
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DISCUSSION 
 
The present study provides the first pharmacological evidence for 
adenosine A2ARs exerting a negative control on the α6β2-containing nAChR-
mediated stimulation of dopamine release from striatal dopaminergic terminals. 
This observation strengthens the notion that A2ARs mainly act as fine-tuners of 
different other neurotransmitters systems (Sebastião and Ribeiro, 2009). In fact, 
striatal presynaptic A2ARs can negatively control metabotropic receptors such 
as adenosine A1Rs (Ciruela et al., 2006) and cannabinoid CB1 receptors 
(CB1Rs) (Martíre et al., 2011), as well as potentiate glutamate metabotropic 
group 5 receptors (mGluR5, Rodrigues et al., 2005) or catalytic receptors, such 
as glial cell line-derived neurotrophic factor  (GDNF) receptors (Gomes et al., 
2006, 2009). In other brain areas, A2ARs also have been shown to control the 
function of ionotropic receptors, such as N-methyl-D-aspartate (NMDA) (Rebola 
et al., 2008), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
(Dias et al., 2012) or γ-aminobutyric acid (GABA)A receptors (Roseti et al., 
2008). Additionally, A2ARs also control the rate of desensitization of different 
nAChRs in peripheral preparations, including the myenteric plexus (Duarte-
Araújo et al., 2004) and the carotid body (Fitzgerald et al., 2009), or in 
heterologous expression systems (Di Angelantonio et al., 2011). The present 
work extends the understanding of control of the function of ionotropic receptors 
to the CNS, in particular to α6β2-containing nAChRs in striatal dopaminergic 
terminals, which are shown to be controlled by A2ARs. 
The Western blot results obtained in this study, detailing the synaptic and 
subsynaptic distribution of some of the main subunits of nAChRs, demonstrated 
that in rodent striatum the α7, α6, α4 and β2 nAChR subunits are localized at 
nerve terminals, were they are able to modulate neurotransmitter release. The 
localization of these nAChR subunits in nerve terminals of the striatum has 
already been reported (Jones et al., 2001; Marchi et al., 2002; Zoli et al., 2002; 
Grady et al., 2007), but very little data was previously available on their 
subsynaptic localization, particularly the presence in the presynaptic active 
zone. Indeed, the use of a fractionation methodology that accomplishes the 
separation of pre-, post- and extra-synaptic fractions allows a comprehensive 
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discernment of the distribution of the various nAChR subunits in the different 
synaptic zones of the nerve terminals. 
The α7 nAChRs, commonly composed by a pentamer of α7 subunits, have 
been shown to be present in glutamatergic terminals of rat and human striatum 
(Marchi et al., 2002), among other brain areas (Jones and Wonnacott, 2004) 
where they modulate glutamate release. However, α7 nAChRs seem to be 
absent from mesolimbic dopaminergic neurons (Zoli et al., 2002). Our results 
support these observations since it was detected α7 subunit immunoreactivity in 
the rat striatal nerve terminals and a predominant presynaptic localization at the 
subsynaptic level, both in the active zone and in extrasynaptic sites. However, 
using an antagonist against the α7 nAChRs, we observed that these receptors 
are not involved in mediating the nicotine-stimulated dopamine release from 
isolated nerve terminals. This is probably due to α7 nAChRs being 
predominantly present in glutamatergic rather than dopaminergic terminals 
(Kaiser and Wonnacott, 2000; Marchi et al., 2002; Zoli et al., 2002; Grady et al., 
2007) or because of their low affinity for nicotine (Köfalvi et al., 2000; Toyohara 
and Hashimoto 2010).  The α7 nAChRs have also been localized in glial cells, 
such as microglia and astrocytes, playing a role in modulating immunological 
responses (Conejero-Goldberg et al., 2008) and in that way these non-neuronal 
α7 nAChRs could tentatively be included in the synaptosomal membrane 
samples, adding to the immunoreactivity of the α7 subunit observed in the 
Western blot assay. However, the isolation procedure using percoll yields 
purified synaptosomal membranes, which have a low content of glial 
membranes (Turner and Backelard, 1987), thus assuring the predominant 
neuronal origin of the synaptosomal samples. Although our observations clearly 
highlight the possible importance of the α7 nAChRs as presynaptic modulators 
of neurotransmitters release, our data obtained using isolated subsynaptic 
fractions also show the presence of the α7 subunit in striatal postsynaptic 
terminals (albeit at low levels), where they might play a role in fast direct 
synaptic transmission. Indeed, this process of fast synaptic transmission was 
shown to be mediated by α7 nAChRs in the hippocampus (see Dani and 
Bertrand, 2007; Albuquerque et al., 2009).  
Our data also showed that the β2 subunit of nAChRs was localized in 
synaptosomal membranes, supporting the notion that this subunit is 
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predominant in striatum nerve terminals. The β2 subunit is not able to form 
functional nAChRs by itself, as does the α7 subunit, so it assembles with other 
nAChR subunits like the α4 and α6 (Gotti et al., 2007). Consequently, the β2 
subunit is a component of different main nAChR subtypes identified in the 
striatum, such as the α4β2* and α6β2* nAChRs (see Grady et al., 2007). In fact, 
immunoprecipitation studies suggest that all nAChRs present in dopamine axon 
terminals contain the β2 subunit (Champtiaux et al., 2003; Salminen et al., 
2004).  
Regarding the distribution of α4 subunit it was observed that it is localized 
in nerve terminals as demonstrated by the immunolabeling of the subunit in 
purified synaptosomes. Notably, the subsynaptic distribution of the α4 subunit 
closely resembles that of the β2 subunit since in the striatum of rats both 
subunits were predominantly detected in the extrasynaptic fraction, outside the 
active zone, and in the striatum of mice the two subunits were mainly found in 
the presynaptic fraction, at the synaptic active zone. This is not surprising 
considering that together they can form α4β2* nAChRs subtypes, which are the 
most abundant in the rodent striatum (Grady et al., 2007), and also in the 
mammalian brain (Millar and Gotti, 2009). The synaptic and subsynaptic 
distribution observed for the α4 and β2 subunits is in agreement with several 
studies that have reported that the α4 and β2 subunits are localized in striatal 
dopaminergic and GABAergic nerve terminals, and participate in the modulation 
of dopamine and GABA release (Kaiser and Wonnacott, 2000; Zoli et al., 2002; 
Grady et al., 2007; Exley and Cragg, 2008, Exley et al., 2012). The predominant 
localization of these subunits in the synaptic active zone and in synaptic regions 
outside the active zone, observed in the present study, highlights the reported 
capacity of β2* nAChR subtypes to modulate neurotransmitter release both 
directly and indirectly. Indeed, the α4β2* (non-α6) nAChRs likely mediated a 
fraction of the nicotine-induced [3H]dopamine release observed in this study.   
 The results obtained for the localization of the α6 subunit reveal that it is 
present in striatal nerve terminals, as determined by the labeling of striatal 
synaptic membranes with a subunit selective antibody. Surprisingly, at the 
subsynaptic level the α6 subunit was mostly observed postsynaptically, albeit 
being also significantly present in the presynaptic and extrasynaptic fractions. In 
a different way, previous studies concerning the localization of the α6* nAChRs 
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strongly suggested a predominant presynaptic localization of these receptor 
subtypes in dopaminergic nerve terminals (see Zoli et al., 2002; Yang et al., 
2009; Quik et al., 2011) which represent only about 1/5 of the total number of 
nerve terminals in the striatum (Borycz et al., 2007; Gomes et al., 2009). We 
confirmed our results by using a second α6 subunit specific antibody (raised 
against the carboxyl-terminus of human CHRNA6, not shown) and the data 
obtained confirm the predominant postsynaptic localization of the α6 subunit. 
Recent studies suggest that functional postsynaptic α6* nAChRs are located on 
somatodendrites of dopaminergic neurons in the ventral tegmental area 
(Drenan et al., 2008). Our results prompt us to contend for an unreported role of 
postsynaptic α6* nAChRs in mediating cholinergic transmission; or for the 
putative existence of an unidentified α6-containing nAChR subtype in striatal 
postsynaptic regions. Although our data showed a main localization of the α6 
subunit in postsynaptic fractions, this subunit was also identified at presynaptic 
and extrasynaptic locations, consistent with the α6* nAChRs function to 
modulate neurotransmitter release (see Yang et al., 2009; Quik et al., 2011). 
Consequently, we observed that α6* nAChRs are responsible for modulating 
~70% of the dopamine release induced by nicotine, in isolated striatal nerve 
terminals, thus confirming the reports that indicate the α6-containing nAChRs as 
main players in regulating dopamine release in the striatum (see Yang et al., 
2009; Quik et al., 2011).  
The subsynaptic distribution of the α7, α4, α6 and β2 subunits of nAChRs 
was assessed in nerve terminals from both Wistar rats and C57BL/6 mice, 
allowing us to conclude that the localization of the subunits is similar between 
the two species. The results highlight however a substantial difference in the 
localization of the α4 and β2 subunits within the nerve terminals (presynaptic 
active zone and extrasynaptic locals), between Wistar rats and C57BL/6 mice. 
Taken together the data obtained about the synaptic and subsynaptic 
distributon of different nAChR subunits, combined with the pharmacological 
characterization of nAChRs that control dopamine release induced by nicotine, 
indicate an important role of the α6β2-containing nAChRs to mediate the 
dopamine releasing action of nicotine. This is in agreement with previous 
findings showing that the absence of β2 subunits abrogates the ability of 
nicotine to trigger dopamine release from synaptosomes obtained from three 
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different mouse brain regions, striatum, nucleus accumbens and olfactory 
tubercle (Grady et al., 2002). Moreover, it was also demonstrated that the α6 
subunit has an important role in the regulation of mesolimbic dopamine release 
(Calabresi and Di Filippo, 2008; Drenan et al., 2008; Meyer et al., 2008; Quik et 
al., 2011). 
In the present study, the contention for the involvement of A2ARs in 
controlling nAChRs function was based on the antagonism of the effect of 
CGS21680 (inhibition) by ZM241385 (facilitation) on nicotine-induced dopamine 
release in striatal synaptosomes. Since ZM241385 can also block A2BRs, 
although with a 10-fold lower potency to inhibit A2BRs compared to A2ARs 
(Poucher et al., 1995; Ji and Jacobson, 1999), we also probed the possible 
involvement of A2BRs in facilitating the nicotine-stimulated dopamine release. 
The data obtained showed that the selective A2BR antagonist, MRS1754 largely 
inhibited (contrarily to the potentiation observed with ZM241385) the effect of 
nicotine at a concentration (200 nM) three-fold lower than its IC50 at A2ARs. 
Furthermore, our data showed that the concomitant inhibition of both A2ARs and 
A2BRs extinguished each other's effect. This may mean two subsets of 
dopaminergic terminals bearing either A2ARs or A2BRs, leading to a lack of net 
change, or alternatively that the two receptors may reside and interact in the 
same nerve terminals. Intriguingly, neither ZM241385 nor MRS1754 affected 
dopamine release per se, but when combined they synergistically stimulated 
dopamine release. This was also observed when testing the non-selective 
adenosine receptor antagonist, caffeine, an observation that may be pertinent to 
the understanding of the addictive profile of caffeine (Svikis et al., 2005). 
Although the underlying mechanism for how A2AR activation or the 
simultaneous A2AR/A2BR blockade increases basal dopamine outflow is unclear, 
these data provide the first demonstration of a functional interaction between 
the two A2R subtypes in the CNS, in a manner similar to that previously 
reported to occur in splenocytes (Moriyama and Sitkovsky, 2010). Apart from 
the ability of A2ARs to control the α6β2-containing nAChR-induced release of 
dopamine, the present results also showed that CGS21680 per se stimulated 
the release of dopamine; this is in agreement with functional and morphological 
data identifying the presence of A2ARs in dopaminergic nerve endings in the 
striatum (Chowdhury and Fillenz, 1991; Gomes et al., 2006, 2009) and also, 
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with the ability of striatally microinfused CGS21680 to increase basal dopamine 
levels in freely moving rats (Gołembiowska and Zylewska, 1997). 
In order to assess if extrasynaptosomal adenosine might be responsible 
for tonic activation of adenosine receptors, the levels of this nucleoside were 
measured in the synaptosomal preparation. Extracellular adenosine was 
detected, which shows that adenosine is indeed released by synaptosomes. 
Furthermore, we found that nicotine did not modify the extracellular levels of 
adenosine. These results clearly support the notion that, in our system, there is 
always a tonic activation of adenosine receptors by endogenous extracellular 
adenosine, which explains the ability of the antagonists of adenosine receptors 
to modify the dopamine release from superfused synaptosomes.  
The ability of presynaptic A2ARs to control the α6β2-containing nAChR-
induced release of dopamine was extended to an in vivo setting, by showing 
that A2ARs also control the locomotor sensitization induced by nicotine. This 
locomotor sensitization to nicotine is known to involve the recruitment of β2-
containing nAChRs (Picciotto et al., 1998) and a differential participation of α4* 
and α6* nAChRs, but not of α7 nAChRs (Kempsill and Pratt, 2000; Tapper et 
al., 2004; Gotti et al., 2010; Smith et al., 2010), controlling the release of 
dopamine in different regions of the basal ganglia. This differential adaptation of 
different α4-containing and α6-containing nAChRs upon repeated nicotinic 
exposure (Tapper et al., 2004; Perry et al., 2007; Perez et al., 2008; Smith et 
al., 2010) is a likely explanation for the potentiation of nicotinic locomotor 
sensitization by the tested A2AR antagonist. This is in general agreement with 
previous studies showing that the non-selective adenosine receptor antagonist, 
caffeine, bolsters the nicotine-induced increase of locomotor activity (Cohen et 
al., 1991). However, it is worth noting that the rewarding properties of nicotine, 
tested in a place-conditioning paradigm, were decreased in global A2AR 
knockout mice (Castañé et al., 2006); heralding the hypothesis that different 
subtypes of nAChRs might be differently controlled by A2ARs.  
In conclusion, this work details the diverse distribution of the subunits that 
constitute some of the main nAChR subtypes in the striatum. The localization of 
the receptors in the various compartments at the synapse relate to the function 
they perform in the neuronal cells, and our results relevantly show the presence 
of nAChR subtypes located presynaptically, and especially in the presynaptic 
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active zone, where they are able to directly modulate neurotransmitter release. 
Accordingly we present, to our knowledge, the first report of a functional 
interaction between nicotinic and adenosine receptors in the striatum i.e, that 
A2ARs curtail the function of α6β2-containing nAChRs in striatal dopaminergic 
nerve terminals, an effect that seems relevant for the ability of A2AR antagonists 
to potentiate the psychomotor effects resulting from a repeated exposure to 
nicotine. These observations provide a mechanistic insight to explain the 
frequent correlation in nicotine and caffeine abuse (Swanson et al., 1994). This 
A2AR-nAChR interaction also paves the way to foster novel therapeutic 
opportunities to manage motor diseases related with dysfunctional dopamine 
signalling such as Parkinson’s disease, where both caffeine and nicotine 
provide a combined prophylactic benefit (Powers et al., 2008) and where A2AR 
antagonists are a leading non-dopaminergic therapeutic strategy (Prediger, 
2010; Hickey and Stacy, 2012). 
Interestingly, the mechanisms underlying the A2AR-mediated amelioration 
of Parkinson's disease symptoms are not fully understood and it is also possible 
that it may involve a rescuing of nAChRs-stimulated phasic dopamine release 
(see Threlfell et al., 2012), inviting further investigation. 
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MAIN CONCLUSIONS 
 
1. The subunits α7, α4, β2 and α6 of nAChRs were identified by Western 
blot in the terminals (synaptosomes) of striatal neurons from Wistar rats 
and C57BL/6 mice. 
 
2. At the synapse of rodent striatal neurons the α7 subunit was enriched in 
the presynaptic active zone, the α4 and β2 subunits were mostly present 
in the presynaptic active zone and in extrasynaptic sites whereas the α6 
subunit was primarily localized in the postsynaptic region.  
 
3. Nicotine induced the release of dopamine from rat striatal nerve 
terminals in a concentration-dependent manner. The A2AR agonist 
CGS21680 inhibited whereas the A2AR antagonist ZM241385 facilitated 
the nicotine-stimulated release of dopamine, revealing a previously 
unknown functional interaction between nAChRs and A2ARs in the 
striatum. 
 
4.  The blockade of the α6-containing nAChRs by a selective antagonist 
abolished the action of the A2AR ligands CGS21680 and ZM241385 on 
the nicotine-stimulated dopamine release from nerve terminals of the 
striatum, implicating the α6-containing nAChR subtypes as the targets for 
control by A2ARs. 
 
5. The locomotor activity of rats increased when treated with the A2AR 
antagonist ZM241385 in addition to nicotine. The increase in locomotor 
activity persisted even after a withdrawal period, thus demonstrating the 
in vivo relevance of the interaction between nAChRs and A2ARs. 
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